{"matching_results": 25580, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1158, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 923}, {"key": "negative", "matching_results": 214}, {"key": "neutral", "matching_results": 21}]}]}, {"key": "wkrb13.com", "matching_results": 1002, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 848}, {"key": "negative", "matching_results": 154}]}]}, {"key": "tickerreport.com", "matching_results": 994, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 892}, {"key": "negative", "matching_results": 102}]}]}, {"key": "watchlistnews.com", "matching_results": 984, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 832}, {"key": "negative", "matching_results": 152}]}]}, {"key": "zolmax.com", "matching_results": 934, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 778}, {"key": "negative", "matching_results": 156}]}]}, {"key": "thelincolnianonline.com", "matching_results": 827, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 678}, {"key": "negative", "matching_results": 149}]}]}, {"key": "dailypolitical.com", "matching_results": 772, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 652}, {"key": "negative", "matching_results": 119}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 715, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 591}, {"key": "negative", "matching_results": 124}]}]}, {"key": "freelancer.com.co", "matching_results": 402, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 358}, {"key": "negative", "matching_results": 42}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "ecommerce.matrix-e.com", "matching_results": 380, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 265}, {"key": "negative", "matching_results": 115}]}]}]}], "results": [{"id": "7C5IVQDqqoxJG3aO3Q_ek0AQaJxpZUXbaF49ZFifvNnz-_d-JpK5_1rz5J8gNIMv", "result_metadata": {"score": 37.7519}, "author": "Swapna", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.5%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": -0.569155, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Dengue fever", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}, {"text": "Arithmetic mean", "relevance": 0.820831, "dbpedia_resource": "http://dbpedia.org/resource/Arithmetic_mean"}], "categories": [{"score": 0.590152, "label": "/health and fitness/disease"}, {"score": 0.55646, "label": "/health and fitness/disease/epidemic"}, {"score": 0.356313, "label": "/health and fitness/disease/cold and flu"}], "relations": [], "keywords": [{"text": "Dengue Vaccine", "sentiment": {"score": -0.581441, "label": "negative"}, "relevance": 0.908306}, {"text": "forecast period", "sentiment": {"score": -0.581441, "label": "negative"}, "relevance": 0.722829}, {"text": "CAGR", "sentiment": {"score": -0.581441, "label": "negative"}, "relevance": 0.37362}]}, "crawl_date": "2018-11-09T17:56:05Z", "url": "https://www.findmarketresearch.org/2018/07/dengue-vaccine-market-is-expected-to-expand-at-a-17-5-cagr-over-the-forecast-period-2017-2027/", "host": "findmarketresearch.org", "text": "Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-07-12T09:02:00+05:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.5609, "label": "negative"}, "text": "dengue", "relevance": 0.834545, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}, {"count": 2, "sentiment": {"score": -0.616433, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.380114, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi S.A.", "relevance": 0.363501, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 2, "sentiment": {"score": -0.480115, "label": "negative"}, "text": "Mn", "relevance": 0.318346, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.259379, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.259372, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.750475, "label": "negative"}, "text": "Latin America", "relevance": 0.228592, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biological E. Limited", "relevance": 0.226421, "type": "Company", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Panacea Biotech Ltd.", "relevance": 0.22559, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Butantan Institute", "relevance": 0.215611, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.20553, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.200703, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.3%", "relevance": 0.200703, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.4%", "relevance": 0.200703, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70.3%", "relevance": 0.200703, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.200703, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.534191, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Burdening occurrence of dengue fever across the Asia-Pacific region", "keywords": [{"text": "dengue fever"}, {"text": "Asia-Pacific region"}, {"text": "occurrence"}]}, "sentence": "Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise.", "object": {"text": "the demand for effective vaccines and medications", "keywords": [{"text": "effective vaccines"}, {"text": "demand"}, {"text": "medications"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has prompted", "normalized": "have prompt"}}, {"subject": {"text": "Burdening occurrence of dengue fever across the Asia-Pacific region", "keywords": [{"text": "dengue fever"}, {"text": "Asia-Pacific region"}, {"text": "occurrence"}]}, "sentence": "Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise.", "object": {"text": "the demand for effective vaccines and medications to supress this viral malaise", "keywords": [{"text": "viral malaise"}, {"text": "effective vaccines"}, {"text": "demand"}, {"text": "medications"}]}, "action": {"verb": {"text": "prompt", "tense": "past"}, "text": "has prompted", "normalized": "have prompt"}}, {"subject": {"text": "several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "to develop a cure for dengue", "keywords": [{"text": "dengue"}, {"text": "cure"}], "entities": [{"type": "HealthCondition", "text": "dengue", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}]}, "action": {"verb": {"text": "strive", "tense": "present"}, "text": "striving", "normalized": "strive"}}, {"subject": {"text": "several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "a cure for dengue", "keywords": [{"text": "dengue"}, {"text": "cure"}], "entities": [{"type": "HealthCondition", "text": "dengue", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "are striving to develop", "normalized": "be strive to develop"}}, {"subject": {"text": "the fever\u2019s incidence rate in Asia-Pacific", "keywords": [{"text": "incidence rate"}, {"text": "Asia-Pacific"}, {"text": "fever"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "rising at an alarming rate", "keywords": [{"text": "rate"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the fever\u2019s incidence rate in Asia-Pacific", "keywords": [{"text": "incidence rate"}, {"text": "Asia-Pacific"}, {"text": "fever"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "at an alarming rate", "keywords": [{"text": "rate"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "is rising", "normalized": "be rise"}}, {"subject": {"text": "by Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "A recent report", "keywords": [{"text": "recent report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "A recent report published by Future Market Insights", "keywords": [{"text": "Future Market Insights"}, {"text": "recent report"}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific", "keywords": [{"text": "global dengue vaccines"}, {"text": "Asia-Pacific"}, {"text": "70.3"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Quantity", "text": "70.3"}]}, "action": {"verb": {"text": "predict", "tense": "present"}, "text": "predicts", "normalized": "predict"}}, {"subject": {"text": "by Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "an estimated 70.3% of global dengue vaccines market", "keywords": [{"text": "global dengue vaccines"}, {"text": "70.3"}, {"text": "market"}], "entities": [{"type": "Quantity", "text": "70.3"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will be dominated", "normalized": "will be dominate"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.", "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue to be", "normalized": "will continue to be"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.", "object": {"text": "the largest market", "keywords": [{"text": "largest market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will continue to be", "normalized": "will continue to be"}}, {"subject": {"text": "$ 288.7 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 288.7"}]}, "sentence": " Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "object": {"text": "in US", "entities": []}, "action": {"verb": {"text": "rake", "tense": "future"}, "text": "is expected to rake", "normalized": "be expect to rake"}}, {"subject": {"text": "The report, titled \u201c Dengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027 ,\u201d", "keywords": [{"text": "Dengue Vaccines Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}]}, "sentence": " The report, titled \u201c Dengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027 ,\u201d expects that more and more pharmaceutical giants from across the globe will be partaking in the market\u2019s growth in the years to come.", "object": {"text": "that more and more pharmaceutical giants from across the globe will be partaking in the market\u2019s growth in the years to come", "keywords": [{"text": "pharmaceutical giants"}, {"text": "globe"}, {"text": "market"}, {"text": "growth"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd.", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Biological E. Limited"}, {"text": "Panacea Biotech"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}, {"type": "Company", "text": "Panacea Biotech Ltd."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development", "keywords": [{"text": "Panacea Biotech Ltd."}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Biological E. Limited"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}, {"type": "Company", "text": "Panacea Biotech Ltd."}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "is witnessing", "normalized": "be witness"}}, {"subject": {"text": "by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Biological E. Limited"}, {"text": "Co. Inc."}], "entities": [{"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "vaccines", "keywords": [{"text": "vaccines"}]}, "action": {"verb": {"text": "formulate", "tense": "past"}, "text": "being formulated", "normalized": "be formulate"}}, {"subject": {"text": "government institutes", "keywords": [{"text": "government institutes"}]}, "sentence": " The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "action": {"verb": {"text": "remain", "tense": "future"}, "text": "will remain", "normalized": "will remain"}}, {"subject": {"text": "a little less than US$ 650 Mn worth of revenues", "keywords": [{"text": "Mn worth"}, {"text": "revenues"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "object": {"text": "from sales of dengue vaccines across government institutes", "keywords": [{"text": "dengue vaccines"}, {"text": "sales"}, {"text": "government"}]}, "action": {"verb": {"text": "arise", "tense": "future"}, "text": "is expected to arise", "normalized": "be expect to arise"}}, {"subject": {"text": "hospitals", "keywords": [{"text": "hospitals"}]}, "sentence": " Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will also dominate", "normalized": "will also dominate"}}, {"subject": {"text": "hospitals", "keywords": [{"text": "hospitals"}]}, "sentence": " Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR.", "object": {"text": "a 17.3% revenue CAGR", "keywords": [{"text": "revenue CAGR"}], "entities": [{"type": "Quantity", "text": "17.3"}]}, "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market, at present, will witness sales of the sole of vaccine, Dengvaxia, developed by Sanofi.", "object": {"text": "sales of the sole of vaccine, Dengvaxia, developed by Sanofi", "keywords": [{"text": "Sanofi"}, {"text": "sole"}, {"text": "vaccine"}, {"text": "sales"}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "will witness", "normalized": "will witness"}}, {"subject": {"text": "factors shaping up the dynamics of global dengue vaccines market", "keywords": [{"text": "global dengue vaccines"}, {"text": "factors"}, {"text": "dynamics"}, {"text": "market"}], "entities": []}, "sentence": " Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are:", "action": {"verb": {"text": "compile", "tense": "past"}, "text": "compiled", "normalized": "compile"}}, {"subject": {"text": "the economic turmoil in Latin America", "keywords": [{"text": "economic turmoil"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market\u2019s growth", "keywords": [{"text": "global market"}, {"text": "growth"}], "entities": []}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level", "object": {"text": "at a macroeconomic level", "keywords": [{"text": "macroeconomic level"}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "is projected to impact", "normalized": "be project to impact"}}, {"subject": {"text": "growth", "keywords": [{"text": "growth"}]}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "lack of skilled professionals and unavailability of optimum diagnostic systems", "keywords": [{"text": "optimum diagnostic systems"}, {"text": "skilled professionals"}, {"text": "lack"}, {"text": "unavailability"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "has given", "normalized": "have give"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "being treated as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "treated as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "is being treated", "normalized": "be be treat"}}, {"subject": {"text": "The global market for dengue vaccines", "keywords": [{"text": "dengue vaccines"}, {"text": "global market"}], "entities": []}, "sentence": " The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group", "object": {"text": "an opportunistic breakthrough", "keywords": [{"text": "opportunistic breakthrough"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "drugmakers", "keywords": [{"text": "drugmakers"}]}, "sentence": " The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group", "object": {"text": "effective vaccines", "keywords": [{"text": "effective vaccines"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "A Sample Report", "keywords": [{"text": "Sample Report"}]}, "sentence": " A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "object": {"text": "Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "keywords": [{"text": "Request"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Fever", "relevance": 0.972473, "dbpedia_resource": "http://dbpedia.org/resource/Fever"}, {"text": "Dengue fever", "relevance": 0.773879, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}, {"text": "GlaxoSmithKline", "relevance": 0.754636, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Malaria", "relevance": 0.753416, "dbpedia_resource": "http://dbpedia.org/resource/Malaria"}, {"text": "Pharmaceutical industry", "relevance": 0.736857, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.612608, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Revenue", "relevance": 0.600271, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Asia-Pacific", "relevance": 0.591838, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Dengue", "relevance": 0.57362, "dbpedia_resource": "http://dbpedia.org/resource/Dengue"}, {"text": "Biotechnology", "relevance": 0.558572, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Economics", "relevance": 0.53505, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Sanofi-Aventis", "relevance": 0.529322, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Pharmacology", "relevance": 0.479077, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Aspirin", "relevance": 0.46714, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Vaccine", "relevance": 0.441348, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "Influenza", "relevance": 0.436291, "dbpedia_resource": "http://dbpedia.org/resource/Influenza"}, {"text": "Macroeconomics", "relevance": 0.433607, "dbpedia_resource": "http://dbpedia.org/resource/Macroeconomics"}], "categories": [{"score": 0.786115, "label": "/health and fitness/disease"}, {"score": 0.461076, "label": "/health and fitness/disease/epidemic"}, {"score": 0.241284, "label": "/health and fitness/disease/cold and flu"}], "relations": [{"type": "agentOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.711673, "arguments": [{"text": "Future Market Insights", "location": [347, 369], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [334, 343], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.85028, "arguments": [{"text": "Future Market Insights", "location": [347, 369], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "predicts", "location": [370, 378], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.617823, "arguments": [{"text": "Merck & Co. Inc.", "location": [1285, 1301], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1184, 1193], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.564008, "arguments": [{"text": "Vabiotech", "location": [1303, 1312], "entities": [{"type": "Organization", "text": "Vabiotech", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1184, 1193], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.537026, "arguments": [{"text": "Butantan Institute", "location": [1314, 1332], "entities": [{"type": "Organization", "text": "Butantan Institute", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1184, 1193], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "employedBy", "sentence": "The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "score": 0.943342, "arguments": [{"text": "institutes", "location": [1444, 1454], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "government", "location": [1433, 1443], "entities": [{"type": "GeopoliticalEntity", "text": "government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.931626, "arguments": [{"text": "institutes", "location": [1653, 1663], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "government", "location": [1642, 1652], "entities": [{"type": "GeopoliticalEntity", "text": "government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "score": 0.748367, "arguments": [{"text": "institutes", "location": [1444, 1454], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "dengue vaccines", "location": [1492, 1507], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "hasAttribute", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.821245, "arguments": [{"text": "institutes", "location": [1653, 1663], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "dengue vaccines", "location": [1619, 1634], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "agentOf", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.59603, "arguments": [{"text": "Mn", "location": [1563, 1565], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "arise", "location": [1599, 1604], "entities": [{"type": "EventCommunication", "text": "arise"}]}]}, {"type": "instrumentOf", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.244216, "arguments": [{"text": "dengue", "location": [2002, 2008], "entities": [{"type": "HealthCondition", "text": "dengue fever"}]}, {"text": "outbreak", "location": [1990, 1998], "entities": [{"type": "NaturalDisaster", "text": "outbreak"}]}]}, {"type": "locatedAt", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.390575, "arguments": [{"text": "outbreak", "location": [1990, 1998], "entities": [{"type": "NaturalDisaster", "text": "outbreak"}]}, {"text": "countries", "location": [2020, 2029], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.581907, "arguments": [{"text": "countries", "location": [2020, 2029], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Latin America", "location": [2055, 2068], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.576976, "arguments": [{"text": "patients", "location": [2259, 2267], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "makers", "location": [2241, 2247], "entities": [{"type": "Organization", "text": "makers"}]}]}, {"type": "timeOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.781182, "arguments": [{"text": "2017", "location": [387, 391], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "predicts", "location": [370, 378], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "hasAttribute", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.763484, "arguments": [{"text": "drugmakers", "location": [2533, 2543], "entities": [{"type": "Person", "text": "drugmakers"}]}, {"text": "dengue vaccines", "location": [2476, 2491], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "employedBy", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.487861, "arguments": [{"text": "Sample Report", "location": [2620, 2633], "entities": [{"type": "Person", "text": "Sample Report"}]}, {"text": "group", "location": [2612, 2617], "entities": [{"type": "Organization", "text": "makers"}]}]}, {"type": "agentOf", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group A Sample Report is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1763", "score": 0.872514, "arguments": [{"text": "Sample Report", "location": [2620, 2633], "entities": [{"type": "Person", "text": "Sample Report"}]}, {"text": "Request", "location": [2652, 2659], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "locatedAt", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.550537, "arguments": [{"text": "Pacific", "location": [471, 478], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [466, 470], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "score": 0.508396, "arguments": [{"text": "Mn", "location": [785, 787], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "dengue vaccines", "location": [731, 746], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "hasAttribute", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.556831, "arguments": [{"text": "Mn", "location": [1563, 1565], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "dengue vaccines", "location": [1619, 1634], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "populationOf", "sentence": "Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "score": 0.574871, "arguments": [{"text": "288.7", "location": [779, 784], "entities": [{"type": "Cardinal", "text": "288.7"}]}, {"text": "US$", "location": [775, 778], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.816563, "arguments": [{"text": "drugmaker", "location": [1125, 1134], "entities": [{"type": "Person", "text": "Sanofi S.A."}]}, {"text": "French", "location": [1118, 1124], "entities": [{"type": "GeopoliticalEntity", "text": "French", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.703763, "arguments": [{"text": "Biological E. Limited", "location": [1202, 1223], "entities": [{"type": "Organization", "text": "Biological E. Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1184, 1193], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.829056, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [1225, 1262], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1184, 1193], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.579328, "arguments": [{"text": "GlaxoSmithKline plc", "location": [1264, 1283], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1184, 1193], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}], "keywords": [{"text": "dengue vaccines", "sentiment": {"score": 0.220678, "label": "positive"}, "relevance": 0.940522}, {"text": "dengue vaccines market", "sentiment": {"score": -0.332649, "label": "negative"}, "relevance": 0.814488}, {"text": "global dengue vaccines", "sentiment": {"score": -0.382236, "label": "negative"}, "relevance": 0.711927}, {"text": "dengue fever", "sentiment": {"score": -0.72453, "label": "negative"}, "relevance": 0.545798}, {"text": "Future Market Insights", "sentiment": {"score": -0.397976, "label": "negative"}, "relevance": 0.513944}, {"text": "effective vaccines", "sentiment": {"score": -0.074131, "label": "negative"}, "relevance": 0.506094}, {"text": "projecting revenue growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418782}, {"text": "majority revenue share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41544}, {"text": "Global Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409245}, {"text": "government institutes", "sentiment": {"score": -0.559191, "label": "negative"}, "relevance": 0.408415}, {"text": "Latin America", "sentiment": {"score": -0.750475, "label": "negative"}, "relevance": 0.407958}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.407539}, {"text": "Panacea Biotech Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405808}, {"text": "Biological E. Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403132}, {"text": "comforting vaccine makers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.400023}, {"text": "undistinguished febrile disease", "sentiment": {"score": -0.756735, "label": "negative"}, "relevance": 0.39664}, {"text": "optimum diagnostic systems", "sentiment": {"score": -0.756735, "label": "negative"}, "relevance": 0.394054}, {"text": "global market", "sentiment": {"score": -0.132281, "label": "negative"}, "relevance": 0.391381}, {"text": "second-largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37894}, {"text": "Asia-Pacific region", "sentiment": {"score": -0.692325, "label": "negative"}, "relevance": 0.376873}, {"text": "largest market", "sentiment": {"score": -0.268764, "label": "negative"}, "relevance": 0.374623}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369582}, {"text": "burdening outbreak", "sentiment": {"score": -0.701968, "label": "negative"}, "relevance": 0.368265}, {"text": "viral malaise", "sentiment": {"score": -0.692325, "label": "negative"}, "relevance": 0.368244}, {"text": "pharmaceutical companies", "sentiment": {"score": -0.419831, "label": "negative"}, "relevance": 0.363897}, {"text": "recent report", "sentiment": {"score": -0.397976, "label": "negative"}, "relevance": 0.363667}, {"text": "incidence rate", "sentiment": {"score": -0.753636, "label": "negative"}, "relevance": 0.362294}, {"text": "revenue CAGR", "sentiment": {"score": -0.350706, "label": "negative"}, "relevance": 0.359806}, {"text": "report further reveals", "sentiment": {"score": -0.436632, "label": "negative"}, "relevance": 0.358956}, {"text": "pharmaceutical giants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357567}, {"text": "Opportunity Assessment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357556}, {"text": "GlaxoSmithKline plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357087}, {"text": "opportunistic breakthrough", "sentiment": {"score": 0.618194, "label": "positive"}, "relevance": 0.356828}, {"text": "French drugmaker", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356643}, {"text": "largest end-users", "sentiment": {"score": -0.436632, "label": "negative"}, "relevance": 0.35626}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356248}, {"text": "Butantan Institute", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356178}, {"text": "Sample Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355612}, {"text": "multiple phases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355567}, {"text": "economic turmoil", "sentiment": {"score": -0.750475, "label": "negative"}, "relevance": 0.355424}, {"text": "Mn worth", "sentiment": {"score": -0.68175, "label": "negative"}, "relevance": 0.355237}, {"text": "active participation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354987}, {"text": "macroeconomic level", "sentiment": {"score": -0.750475, "label": "negative"}, "relevance": 0.353898}, {"text": "age group", "sentiment": {"score": 0.618194, "label": "positive"}, "relevance": 0.352859}, {"text": "Available Upon Request", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352434}, {"text": "skilled professionals", "sentiment": {"score": -0.756735, "label": "negative"}, "relevance": 0.350569}, {"text": "sales", "sentiment": {"score": -0.68175, "label": "negative"}, "relevance": 0.317818}, {"text": "revenues", "sentiment": {"score": -0.68175, "label": "negative"}, "relevance": 0.31019}, {"text": "70.3", "sentiment": {"score": -0.47923, "label": "negative"}, "relevance": 0.309795}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.309707}]}, "extracted_metadata": {"sha1": "8d3aa2c5135eafe92c0f1b79d826caf6fd7af977", "filename": "1541786165838.zip-a812c4c7b6205995cee73b5c1c8c3a48.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/dengue-vaccines-market", "https://www.futuremarketinsights.com/reports/sample/REP-GB-1763"], "title": "Dengue Vaccine is expected to expand at a 17.5% CAGR over the forecast period (2017\u20132027)", "forum_title": "Research Insights \u2013 Page 116 \u2013 Find Market Research"}, {"id": "Dqu1np7TUZ3N8M1mjV6J_77QlJeGhLWfvFd4X4y4putvtD2dVfeuHP-VaUZQUwUN", "result_metadata": {"score": 36.9369}, "author": "Ankush Nikam", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hepatocellular Carcinoma HCC Treatment", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.670931, "label": "/health and fitness/disease/cancer"}, {"score": 0.455817, "label": "/health and fitness/therapy"}], "relations": [], "keywords": [{"text": "Hepatocellular Carcinoma HCC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.97277}]}, "crawl_date": "2018-11-10T10:34:59Z", "url": "https://www.findmarketresearch.org/2017/08/forecast-and-analysis-on-hepatocellular-carcinoma-hcc-treatment-market-for-period-2016-2026/", "host": "findmarketresearch.org", "text": "Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2017-08-25T07:31:00+05:00", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.426035, "label": "negative"}, "text": "Hepatocellular carcinoma", "relevance": 0.88878, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 11, "sentiment": {"score": -0.612548, "label": "negative"}, "text": "HCC", "relevance": 0.277797, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver disease", "relevance": 0.0820437, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}}, {"count": 1, "sentiment": {"score": -0.525162, "label": "negative"}, "text": "biliary cirrhosis", "relevance": 0.0727103, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Primary biliary cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Primary_biliary_cirrhosis"}}, {"count": 1, "sentiment": {"score": -0.223199, "label": "negative"}, "text": "cirrhosis", "relevance": 0.0725672, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 1, "sentiment": {"score": -0.209731, "label": "negative"}, "text": "HCV", "relevance": 0.0719825, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}, {"count": 1, "sentiment": {"score": -0.20346, "label": "negative"}, "text": "HCV", "relevance": 0.0672711, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}, {"count": 1, "sentiment": {"score": -0.704143, "label": "negative"}, "text": "U.S.", "relevance": 0.0645579, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.0627129, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": -0.46489, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.0614464, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": -0.569662, "label": "negative"}, "text": "principal", "relevance": 0.0610614, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.0606757, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.0597465, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.0596083, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": -0.305367, "label": "negative"}, "text": "North America", "relevance": 0.0592128, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.0575596, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": -0.295954, "label": "negative"}, "text": "Middle East", "relevance": 0.0567549, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Pvt", "relevance": 0.0558603, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgen Corporation", "relevance": 0.0554438, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.535509, "label": "negative"}, "text": "metabolic syndrome", "relevance": 0.0542172, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Metabolic syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.0536521, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0.267702, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.0533361, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": -0.833957, "label": "negative"}, "text": "Asia", "relevance": 0.0530198, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0526017, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0.263121, "label": "positive"}, "text": "Western Europe", "relevance": 0.0516209, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.833957, "label": "negative"}, "text": "Africa", "relevance": 0.0499925, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.048571, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.333167, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.0468063, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.0464642, "type": "Company"}], "sentiment": {"document": {"score": -0.452579, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Hepatocellular carcinoma (HCC)", "keywords": [{"text": "Hepatocellular carcinoma"}, {"text": "HCC"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": "Hepatocellular carcinoma (HCC) is also known as malignant hepatoma.", "object": {"text": "also known as malignant hepatoma", "keywords": [{"text": "malignant hepatoma"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hepatocellular carcinoma (HCC)", "keywords": [{"text": "Hepatocellular carcinoma"}, {"text": "HCC"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": "Hepatocellular carcinoma (HCC) is also known as malignant hepatoma.", "object": {"text": "as malignant hepatoma", "keywords": [{"text": "malignant hepatoma"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "is also known", "normalized": "be also know"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "object": {"text": "the major malignancy of the liver", "keywords": [{"text": "major malignancy"}, {"text": "liver"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The cells of origin of HCC", "keywords": [{"text": "HCC"}, {"text": "cells"}, {"text": "origin"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.", "object": {"text": "the hepatic stem cells", "keywords": [{"text": "hepatic stem cells"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The hepatic tumors", "keywords": [{"text": "hepatic tumors"}]}, "sentence": " The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases.", "object": {"text": "with local expansion", "keywords": [{"text": "local expansion"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "proliferates", "normalized": "proliferate"}}, {"subject": {"text": "The uncommon hepatocellular carcinoma", "keywords": [{"text": "uncommon hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate during the forecast period.", "object": {"text": "anticipated to witness rise in incidence rate", "keywords": [{"text": "incidence rate"}, {"text": "rise"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The uncommon hepatocellular carcinoma", "keywords": [{"text": "uncommon hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate during the forecast period.", "object": {"text": "rise in incidence rate", "keywords": [{"text": "incidence rate"}, {"text": "rise"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is anticipated to witness", "normalized": "be anticipate to witness"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is currently expected to be the third leading cause of death worldwide.", "object": {"text": "currently expected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is currently expected to be the third leading cause of death worldwide.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "expected", "normalized": "expect"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis.", "object": {"text": "liver disease or cirrhosis", "keywords": [{"text": "liver disease"}, {"text": "cirrhosis"}], "entities": [{"type": "HealthCondition", "text": "liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}}]}, "action": {"verb": {"text": "decompensated", "tense": "past"}, "text": "decompensated", "normalized": "decompensated"}}, {"subject": {"text": "The technological advancements and the routine liver function tests", "keywords": [{"text": "routine liver function"}, {"text": "technological advancements"}]}, "sentence": " The technological advancements and the routine liver function tests are now resulting in the early detection of hepatocellular carcinoma.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "incidences of hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "incidences"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market during the forecast period.", "object": {"text": "with hepatitis C virus", "keywords": [{"text": "hepatitis C virus"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S.", "keywords": [{"text": "intrahepatic bile duct"}, {"text": "incidence rate"}, {"text": "hepatic cancer"}, {"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "object": {"text": "approximately 39,230"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The risk factors", "keywords": [{"text": "risk factors"}]}, "sentence": " The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.", "object": {"text": "with hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The risk factors associated with hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "risk factors"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.", "object": {"text": "Hepatitis B virus", "keywords": [{"text": "Hepatitis B virus"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "cost effective treatment procedures", "keywords": [{"text": "cost effective treatment"}, {"text": "procedures"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "to keep up the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "predict", "tense": "past"}, "text": "predicted", "normalized": "predict"}}, {"subject": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "up the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "keep", "tense": "future"}, "text": "predicted to keep", "normalized": "predict to keep"}}, {"subject": {"text": "side effects", "keywords": [{"text": "effects"}]}, "sentence": " However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "with the chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high cost of treatment", "keywords": [{"text": "high cost"}, {"text": "treatment"}]}, "sentence": " However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "major restraints"}, {"text": "treatment market"}, {"text": "growth"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the global hepatocellular carcinoma (HCC) treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Based on application, the global hepatocellular carcinoma (HCC) treatment market is segmented into: Brachytherapy, Chemotherapy, Local Ablation Therapy; Based on end user type, the global hepatocellular carcinoma (HCC) treatment market is segmented into: Hospitals, Clinics, Cancer rehabilitation centers", "object": {"text": "segmented into: Hospitals, Clinics, Cancer rehabilitation centers", "keywords": [{"text": "Cancer rehabilitation centers"}, {"text": "Hospitals"}, {"text": "Clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inventions in technologies for cancer treatment procedures", "keywords": [{"text": "cancer treatment procedures"}, {"text": "Inventions"}]}, "sentence": " Inventions in technologies for cancer treatment procedures are expected to launch into the market in the forecast period.", "object": {"text": "into the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "launch", "tense": "future"}, "text": "are expected to launch", "normalized": "be expect to launch"}}, {"subject": {"text": "Monoclonal antibodies and other immunological treatments", "keywords": [{"text": "Monoclonal antibodies"}, {"text": "immunological treatments"}]}, "sentence": " Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.", "object": {"text": "generally known"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Monoclonal antibodies and other immunological treatments", "keywords": [{"text": "Monoclonal antibodies"}, {"text": "immunological treatments"}]}, "sentence": " Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.", "object": {"text": "for their lesser side effects and better efficacy", "keywords": [{"text": "better efficacy"}, {"text": "lesser side effects"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "the global Hepatocellular Carcinoma (HCC) treatment market", "keywords": [{"text": "global Hepatocellular Carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "classified into regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global Hepatocellular Carcinoma (HCC) treatment market", "keywords": [{"text": "global Hepatocellular Carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "Africa.Hepatitis B virus"}, {"text": "Middle East"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "Africa.Hepatitis B virus"}, {"text": "Middle East"}, {"text": "HBV"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "action": {"verb": {"text": "find", "tense": "past"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "HBV"}, {"text": "HCV"}, {"text": "infection"}], "entities": [{"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "the most significant cause of hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "significant cause"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "Chronic HBV infection", "keywords": [{"text": "Chronic HBV infection"}]}, "sentence": " Chronic HBV infection is the principal cause of hepatocellular carcinoma in Asia and Africa.", "object": {"text": "the principal cause of hepatocellular carcinoma in Asia and Africa", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "principal cause"}, {"text": "Asia"}, {"text": "Africa"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "HCV infection", "keywords": [{"text": "HCV infection"}]}, "sentence": " HCV infection is the principal cause of hepatocellular carcinoma in North America, Europe, and Japan.", "object": {"text": "the principal cause of hepatocellular carcinoma in North America, Europe, and Japan", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "principal cause"}, {"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The global hepatocellular carcinoma treatment market is expected to grow in future due to increasing investment by multinational companies in the cancer research.", "object": {"text": "in future"}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "Bayer AG", "keywords": [{"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}]}, "sentence": " Bayer AG is one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs.", "object": {"text": "one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "treatment drugs"}, {"text": "HCC"}, {"text": "provider"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Some of the key players in hepatocellular carcinoma treatment market", "keywords": [{"text": "hepatocellular carcinoma treatment"}, {"text": "key players"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt.", "object": {"text": "Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Johnson Pvt"}, {"text": "Merck"}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Johnson & Johnson Pvt"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the antiviral and oncology", "keywords": [{"text": "oncology"}]}, "sentence": " These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "object": {"text": "unmet medical needs", "keywords": [{"text": "unmet medical needs"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.987814, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Liver", "relevance": 0.915654, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Hepatitis C", "relevance": 0.912766, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Cancer", "relevance": 0.879223, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hepatitis B", "relevance": 0.863342, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Hepatology", "relevance": 0.82542, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Hepatitis", "relevance": 0.700561, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Hepatocellular carcinoma", "relevance": 0.621748, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Bilirubin", "relevance": 0.567541, "dbpedia_resource": "http://dbpedia.org/resource/Bilirubin"}, {"text": "Oncology", "relevance": 0.462636, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Liver disease", "relevance": 0.440194, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Liver function tests", "relevance": 0.42019, "dbpedia_resource": "http://dbpedia.org/resource/Liver_function_tests"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.400782, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Liver biopsy", "relevance": 0.390686, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Hepatitis B virus", "relevance": 0.382565, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}, {"text": "Bile duct", "relevance": 0.381165, "dbpedia_resource": "http://dbpedia.org/resource/Bile_duct"}, {"text": "Bristol-Myers Squibb", "relevance": 0.378597, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Liver transplantation", "relevance": 0.356702, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Hepatitis A", "relevance": 0.351319, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_A"}, {"text": "Interferon", "relevance": 0.346357, "dbpedia_resource": "http://dbpedia.org/resource/Interferon"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.344268, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Chemotherapy", "relevance": 0.340061, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Gastroenterology", "relevance": 0.327753, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Immune system", "relevance": 0.31594, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Alanine transaminase", "relevance": 0.304657, "dbpedia_resource": "http://dbpedia.org/resource/Alanine_transaminase"}, {"text": "Cholangiocarcinoma", "relevance": 0.303227, "dbpedia_resource": "http://dbpedia.org/resource/Cholangiocarcinoma"}, {"text": "Bile", "relevance": 0.294165, "dbpedia_resource": "http://dbpedia.org/resource/Bile"}, {"text": "Jade Ribbon Campaign", "relevance": 0.270667, "dbpedia_resource": "http://dbpedia.org/resource/Jade_Ribbon_Campaign"}, {"text": "Hepatitis C virus", "relevance": 0.269661, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}, {"text": "Paclitaxel", "relevance": 0.259627, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Hepatic encephalopathy", "relevance": 0.258127, "dbpedia_resource": "http://dbpedia.org/resource/Hepatic_encephalopathy"}, {"text": "Alcoholic liver disease", "relevance": 0.256069, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholic_liver_disease"}, {"text": "Hepatic portal vein", "relevance": 0.246485, "dbpedia_resource": "http://dbpedia.org/resource/Hepatic_portal_vein"}, {"text": "Alcoholism", "relevance": 0.245395, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}, {"text": "Cholestasis", "relevance": 0.245188, "dbpedia_resource": "http://dbpedia.org/resource/Cholestasis"}, {"text": "North America", "relevance": 0.244191, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Jaundice", "relevance": 0.243462, "dbpedia_resource": "http://dbpedia.org/resource/Jaundice"}, {"text": "Generic drug", "relevance": 0.243019, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Blood transfusion", "relevance": 0.241032, "dbpedia_resource": "http://dbpedia.org/resource/Blood_transfusion"}, {"text": "Primary biliary cirrhosis", "relevance": 0.239104, "dbpedia_resource": "http://dbpedia.org/resource/Primary_biliary_cirrhosis"}, {"text": "Clopidogrel", "relevance": 0.234513, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Wilson's disease", "relevance": 0.224541, "dbpedia_resource": "http://dbpedia.org/resource/Wilson's_disease"}, {"text": "Epidemiology", "relevance": 0.223231, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.222609, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Breast cancer", "relevance": 0.22249, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Gastrointestinal cancer", "relevance": 0.219982, "dbpedia_resource": "http://dbpedia.org/resource/Gastrointestinal_cancer"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.214356, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Carcinoma", "relevance": 0.214161, "dbpedia_resource": "http://dbpedia.org/resource/Carcinoma"}, {"text": "Liver cancer", "relevance": 0.213416, "dbpedia_resource": "http://dbpedia.org/resource/Liver_cancer"}, {"text": "Gallbladder", "relevance": 0.212541, "dbpedia_resource": "http://dbpedia.org/resource/Gallbladder"}], "categories": [{"score": 0.642031, "label": "/health and fitness/disease"}, {"score": 0.455849, "label": "/health and fitness/disease/cancer"}, {"score": 0.399602, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "score": 0.891192, "arguments": [{"text": "patients", "location": [141, 149], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic liver diseases", "location": [155, 177], "entities": [{"type": "HealthCondition", "text": "chronic liver diseases"}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.431826, "arguments": [{"text": "companies", "location": [3751, 3760], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Pfizer Inc.", "location": [3697, 3708], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.790481, "arguments": [{"text": "companies", "location": [3751, 3760], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda Pharmaceutical Co. Ltd.", "location": [3714, 3744], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "score": 0.872374, "arguments": [{"text": "patients", "location": [141, 149], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cirrhosis", "location": [182, 191], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "agentOf", "sentence": "The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.", "score": 0.465097, "arguments": [{"text": "HCC", "location": [216, 219], "entities": [{"type": "Organization", "text": "HCC"}]}, {"text": "investigation", "location": [285, 298], "entities": [{"type": "EventLegal", "text": "investigation"}]}]}, {"type": "populationOf", "sentence": "The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "score": 0.352493, "arguments": [{"text": "39,230", "location": [1135, 1141], "entities": [{"type": "Cardinal", "text": "39,230"}]}, {"text": "U.S.", "location": [1112, 1116], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "score": 0.670053, "arguments": [{"text": "APEJ", "location": [2808, 2812], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}, {"text": "Japan", "location": [2814, 2819], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.811736, "arguments": [{"text": "Some", "location": [3438, 3442], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [3454, 3461], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.423466, "arguments": [{"text": "companies", "location": [3751, 3760], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Celgen Corporation", "location": [3628, 3646], "entities": [{"type": "Organization", "text": "Celgen Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.505414, "arguments": [{"text": "companies", "location": [3751, 3760], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Amgen Inc.", "location": [3648, 3658], "entities": [{"type": "Organization", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.482026, "arguments": [{"text": "companies", "location": [3751, 3760], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Teva pharmaceutical Industries Ltd.", "location": [3660, 3695], "entities": [{"type": "Organization", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "hepatocellular carcinoma", "sentiment": {"score": -0.0512475, "label": "negative"}, "relevance": 0.982148}, {"text": "global hepatocellular carcinoma", "sentiment": {"score": 0.0838345, "label": "positive"}, "relevance": 0.842015}, {"text": "hepatocellular carcinoma treatment", "sentiment": {"score": -0.153609, "label": "negative"}, "relevance": 0.841836}, {"text": "carcinoma treatment market", "sentiment": {"score": -0.153609, "label": "negative"}, "relevance": 0.704861}, {"text": "uncommon hepatocellular carcinoma", "sentiment": {"score": -0.710183, "label": "negative"}, "relevance": 0.584437}, {"text": "HCC", "sentiment": {"score": -0.612548, "label": "negative"}, "relevance": 0.429127}, {"text": "forecast period", "sentiment": {"score": -0.755702, "label": "negative"}, "relevance": 0.39601}, {"text": "hepatitis C virus", "sentiment": {"score": -0.561831, "label": "negative"}, "relevance": 0.395981}, {"text": "chronic liver diseases", "sentiment": {"score": -0.823492, "label": "negative"}, "relevance": 0.373673}, {"text": "hepatic stem cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370103}, {"text": "cost effective treatment", "sentiment": {"score": 0.436389, "label": "positive"}, "relevance": 0.368315}, {"text": "cancer treatment procedures", "sentiment": {"score": -0.818066, "label": "negative"}, "relevance": 0.368285}, {"text": "Chronic HBV infection", "sentiment": {"score": -0.833957, "label": "negative"}, "relevance": 0.368059}, {"text": "liver function tests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366711}, {"text": "intrahepatic bile duct", "sentiment": {"score": -0.704143, "label": "negative"}, "relevance": 0.365918}, {"text": "chronic liver injury", "sentiment": {"score": -0.618258, "label": "negative"}, "relevance": 0.365377}, {"text": "incidence rate", "sentiment": {"score": -0.707163, "label": "negative"}, "relevance": 0.36227}, {"text": "Cancer rehabilitation centers", "sentiment": {"score": -0.379072, "label": "negative"}, "relevance": 0.357434}, {"text": "Local Ablation Therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355625}, {"text": "Teva pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355483}, {"text": "end user type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355018}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354694}, {"text": "unmet medical needs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353878}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353099}, {"text": "Request Report Sample", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35218}, {"text": "North America", "sentiment": {"score": -0.305367, "label": "negative"}, "relevance": 0.349868}, {"text": "principal cause", "sentiment": {"score": -0.569662, "label": "negative"}, "relevance": 0.348941}, {"text": "Hepatitis B virus", "sentiment": {"score": -0.471439, "label": "negative"}, "relevance": 0.342435}, {"text": "hepatic cancer", "sentiment": {"score": -0.704143, "label": "negative"}, "relevance": 0.342195}, {"text": "biliary cirrhosis", "sentiment": {"score": -0.525162, "label": "negative"}, "relevance": 0.341971}, {"text": "HCV infection", "sentiment": {"score": -0.305367, "label": "negative"}, "relevance": 0.341936}, {"text": "alcoholic cirrhosis", "sentiment": {"score": -0.223199, "label": "negative"}, "relevance": 0.341213}, {"text": "intrahepatic region", "sentiment": {"score": -0.43973, "label": "negative"}, "relevance": 0.340429}, {"text": "hepatic tumors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340406}, {"text": "treatment drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.337255}, {"text": "major malignancy", "sentiment": {"score": -0.823492, "label": "negative"}, "relevance": 0.336587}, {"text": "malignant hepatoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335294}, {"text": "distant metastases", "sentiment": {"score": -0.43973, "label": "negative"}, "relevance": 0.334169}, {"text": "Africa.Hepatitis B virus", "sentiment": {"score": -0.295954, "label": "negative"}, "relevance": 0.333692}, {"text": "death worldwide", "sentiment": {"score": -0.401604, "label": "negative"}, "relevance": 0.332326}, {"text": "advanced stage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332136}, {"text": "Amgen Inc.", "sentiment": {"score": 0.267702, "label": "positive"}, "relevance": 0.331931}, {"text": "early detection", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331883}, {"text": "local expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331439}, {"text": "technological advancements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331102}, {"text": "major restraints", "sentiment": {"score": -0.439648, "label": "negative"}, "relevance": 0.331069}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331014}, {"text": "metabolic syndrome", "sentiment": {"score": -0.535509, "label": "negative"}, "relevance": 0.330774}, {"text": "pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330766}, {"text": "high cost", "sentiment": {"score": -0.439648, "label": "negative"}, "relevance": 0.330534}]}, "extracted_metadata": {"sha1": "dca5e04c313ba3f9f619fcb16abd3287730ce81a", "filename": "1541846099560.zip-79cb610f7f1726c5b402b26c0ed2cb21.xml", "file_type": "json"}, "external_links": ["http://www.futuremarketinsights.com/reports/hepatocellular-carcinoma-hcc-treatment-market", "http://www.futuremarketinsights.com/reports/sample/rep-gb-1370"], "title": "Forecast and Analysis on Hepatocellular Carcinoma HCC Treatment for Period (2016-2026)", "forum_title": "Research Insights \u2013 Page 368 \u2013 Find Market Research"}, {"id": "dqH0Z1WxQesI9aGUiImUd6SII-D3HFNW0ymmYji3SYE61aXttMwDGq-du-0VBxkp", "result_metadata": {"score": 36.61377}, "author": "Coherent Market Insights - Pharmaceutical Industry", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PolyPeptide Group", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Peptide Therapeutics In Metabolic Disorders Market", "keywords": [{"text": "Peptide Therapeutics"}, {"text": "Metabolic Disorders Market"}]}, "sentence": "Peptide Therapeutics In Metabolic Disorders Market To Show Significant Growth Over The Forecast Period 2018-2026 With key Vendors AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group", "object": {"text": "Significant Growth Over The Forecast Period 2018-2026 With key Vendors AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group", "keywords": [{"text": "Vendors AstraZeneca plc"}, {"text": "Teva Pharmaceutical Industries"}, {"text": "F. Hoffmann-La Roche"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Roche Ltd"}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "PolyPeptide Group"}]}, "action": {"verb": {"text": "Show", "tense": "future"}, "text": "To Show", "normalized": "To Show"}}], "concepts": [{"text": "Pharmaceutical industry", "relevance": 0.985945, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.846699, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Genentech", "relevance": 0.623161, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.57156, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "InnoMed PredTox", "relevance": 0.549161, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Multinational companies", "relevance": 0.539104, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Hoffmann-La Roche", "relevance": 0.500781, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}], "categories": [{"score": 0.727702, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Vendors AstraZeneca plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.904134}, {"text": "Teva Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.798276}, {"text": "Metabolic Disorders Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.786046}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.761269}, {"text": "Peptide Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.648016}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590439}, {"text": "PolyPeptide Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558216}, {"text": "Forecast Period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531189}, {"text": "Significant Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518936}]}, "crawl_date": "2018-11-09T16:25:29Z", "url": "https://www.openpr.com/news/1359313/Peptide-Therapeutics-In-Metabolic-Disorders-Market-To-Show-Significant-Growth-Over-The-Forecast-Period-2018-2026-With-key-Vendors-AstraZeneca-plc-F-Hoffmann-La-Roche-Ltd-Sanofi-S-A-Teva-Pharmaceutical-Industries-Ltd-PolyPeptide-Group.html", "host": "openpr.com", "text": "Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T15:02:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.458758, "label": "negative"}, "text": "diabetes", "relevance": 0.917448, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": -0.688297, "label": "negative"}, "text": "Diabetes mellitus type 2", "relevance": 0.745576, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "Symptom"], "name": "Diabetes mellitus type 2", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_2"}}, {"count": 1, "sentiment": {"score": -0.43509, "label": "negative"}, "text": "Obesity", "relevance": 0.521148, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.517491, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0.41356, "label": "positive"}, "text": "World Health Organization", "relevance": 0.515049, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.514507, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk A/S", "relevance": 0.500962, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd", "relevance": 0.491765, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.500424, "label": "negative"}, "text": "Rhythm Pharmaceuticals Inc.", "relevance": 0.456613, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.220934, "label": "negative"}, "text": "Takeda Pharmaceuticals Co. Ltd.", "relevance": 0.454567, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bachem Holding AG", "relevance": 0.444366, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PolyPeptide Group", "relevance": 0.404713, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "18 year", "relevance": 0.404713, "type": "Quantity"}], "sentiment": {"document": {"score": -0.069763, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "hormones, neurotransmitters, growth factors, ion channel, and ligands", "keywords": [{"text": "ion channel"}, {"text": "growth factors"}, {"text": "neurotransmitters"}, {"text": "ligands"}]}, "sentence": " Over 7,000 naturally occurring peptides have been identified, which have crucial roles in human physiology, which include hormones, neurotransmitters, growth factors, ion channel, and ligands.", "object": {"text": "crucial roles in human physiology", "keywords": [{"text": "crucial roles"}, {"text": "human physiology"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The structure of these peptides", "keywords": [{"text": "peptides"}, {"text": "structure"}]}, "sentence": " The structure of these peptides is usually complex and these conformations depending upon their environment.", "object": {"text": "usually complex and these conformations", "keywords": [{"text": "conformations"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "around 140 peptide therapeutics", "keywords": [{"text": "peptide therapeutics"}]}, "sentence": " According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials.", "object": {"text": "currently evaluated in clinical trials", "keywords": [{"text": "clinical trials"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "around 140 peptide therapeutics", "keywords": [{"text": "peptide therapeutics"}]}, "sentence": " According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials.", "action": {"verb": {"text": "evaluate", "tense": "past"}, "text": "evaluated", "normalized": "evaluate"}}, {"subject": {"text": "Peptide therapeutics", "keywords": [{"text": "Peptide therapeutics"}]}, "sentence": " Peptide therapeutics are increasingly been used for therapeutics in metabolic diseases and oncology.", "object": {"text": "increasingly been used for therapeutics", "keywords": [{"text": "therapeutics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Peptide therapeutics", "keywords": [{"text": "Peptide therapeutics"}]}, "sentence": " Peptide therapeutics are increasingly been used for therapeutics in metabolic diseases and oncology.", "object": {"text": "for therapeutics in metabolic diseases and oncology", "keywords": [{"text": "metabolic diseases"}, {"text": "therapeutics"}, {"text": "oncology"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are increasingly been used", "normalized": "be increasingly be use"}}, {"subject": {"text": "Diabetes", "keywords": [{"text": "Diabetes"}], "entities": [{"type": "HealthCondition", "text": "Diabetes mellitus type 2", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "Symptom"], "name": "Diabetes mellitus type 2", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_2"}}]}, "sentence": " Rising incidence of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are expected to be factors driving growth of the market.", "object": {"text": "type 2 (T2DM) and Obesity", "keywords": [{"text": "Obesity"}, {"text": "type"}, {"text": "T2DM"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "mellitus", "tense": "present"}, "text": "mellitus", "normalized": "mellitus"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " Rising incidence of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are expected to be factors driving growth of the market.", "object": {"text": "growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014.", "object": {"text": "from diabetes", "keywords": [{"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "the number people suffering from diabetes", "keywords": [{"text": "number people"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014.", "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "the world obesity rate", "keywords": [{"text": "world obesity rate"}]}, "sentence": " Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight.", "object": {"text": "increased three times since 1975 and in 2016", "keywords": [{"text": "times"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the world obesity rate", "keywords": [{"text": "world obesity rate"}]}, "sentence": " Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight.", "object": {"text": "three times", "keywords": [{"text": "times"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "has increased", "normalized": "have increase"}}, {"subject": {"text": "1.9 billion adults (18 year and above)", "keywords": [{"text": "adults"}], "entities": [{"type": "Quantity", "text": "18 year"}]}, "sentence": " Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight.", "object": {"text": "estimated to be overweight", "keywords": [{"text": "overweight"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above)", "keywords": [{"text": "world obesity rate"}, {"text": "times"}, {"text": "adults"}], "entities": [{"type": "Quantity", "text": "18 year"}]}, "sentence": " Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight.", "object": {"text": "to be overweight", "keywords": [{"text": "overweight"}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "high incidence rate of metabolic disorders", "keywords": [{"text": "high incidence rate"}, {"text": "metabolic disorders"}]}, "sentence": " Moreover, high incidence rate of metabolic disorders is expected to propel growth of peptide therapeutics in metabolic disorders market in the near future.", "object": {"text": "growth of peptide therapeutics in metabolic disorders market", "keywords": [{"text": "peptide therapeutics"}, {"text": "metabolic disorders market"}, {"text": "growth"}]}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "is expected to propel", "normalized": "be expect to propel"}}, {"subject": {"text": "the risk of developing type 1 and type 2 diabetes", "keywords": [{"text": "diabetes"}, {"text": "type"}, {"text": "risk"}]}, "sentence": " Among the metabolic disorders, the risk of developing type 1 and type 2 diabetes is related to the combination of variants in multiple genes.", "object": {"text": "related to the combination of variants in multiple genes", "keywords": [{"text": "multiple genes"}, {"text": "combination"}, {"text": "variants"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the risk of developing type 1 and type 2 diabetes", "keywords": [{"text": "diabetes"}, {"text": "type"}, {"text": "risk"}]}, "sentence": " Among the metabolic disorders, the risk of developing type 1 and type 2 diabetes is related to the combination of variants in multiple genes.", "object": {"text": "to the combination of variants in multiple genes", "keywords": [{"text": "multiple genes"}, {"text": "combination"}, {"text": "variants"}]}, "action": {"verb": {"text": "relate", "tense": "past"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "monogenic"}, "sentence": " In rare cases, patients which are monogenic having single gene mutation which can lead to diabetes.", "object": {"text": "single gene mutation which can lead to diabetes", "keywords": [{"text": "single gene"}, {"text": "mutation"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "The first peptide", "keywords": [{"text": "peptide"}]}, "sentence": " The first peptide to be administrated therapeutically was insulin and has been used in the treatment of diabetes.", "object": {"text": "therapeutically was insulin", "keywords": [{"text": "insulin"}]}, "action": {"verb": {"text": "administrate", "tense": "past"}, "text": "to be administrated", "normalized": "to be administrate"}}, {"subject": {"text": "The first peptide to be administrated therapeutically", "keywords": [{"text": "peptide"}]}, "sentence": " The first peptide to be administrated therapeutically was insulin and has been used in the treatment of diabetes.", "object": {"text": "insulin", "keywords": [{"text": "insulin"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Development of novel analogues such as lispro insulin", "keywords": [{"text": "novel analogues"}, {"text": "lispro insulin"}]}, "sentence": " Development of novel analogues such as lispro insulin that is an injection to be taken prior to meal, has also aided in growth of the market.", "object": {"text": "an injection", "keywords": [{"text": "injection"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an injection", "keywords": [{"text": "injection"}]}, "sentence": " Development of novel analogues such as lispro insulin that is an injection to be taken prior to meal, has also aided in growth of the market.", "action": {"verb": {"text": "take", "tense": "past"}, "text": "to be taken", "normalized": "to be take"}}, {"subject": {"text": "Development of novel analogues such as lispro insulin that is an injection to be taken prior to meal,", "keywords": [{"text": "novel analogues"}, {"text": "lispro insulin"}, {"text": "meal"}, {"text": "injection"}]}, "sentence": " Development of novel analogues such as lispro insulin that is an injection to be taken prior to meal, has also aided in growth of the market.", "action": {"verb": {"text": "aid", "tense": "past"}, "text": "has also aided", "normalized": "have also aid"}}, {"subject": {"text": "Another important peptide", "keywords": [{"text": "important peptide"}]}, "sentence": " Another important peptide is glucagon like peptide-1 (GLP-1), which has insulin-releasing properties and also helps to suppress the glucagon level.", "object": {"text": "glucagon", "keywords": [{"text": "glucagon"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The glucose dependent action of GLP-1", "keywords": [{"text": "glucose dependent action"}, {"text": "GLP-1"}]}, "sentence": " The glucose dependent action of GLP-1 is more potent to regulate glucose level after a meal.", "object": {"text": "more potent"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "glucose level", "keywords": [{"text": "glucose level"}]}, "sentence": " The glucose dependent action of GLP-1 is more potent to regulate glucose level after a meal.", "action": {"verb": {"text": "regulate", "tense": "future"}, "text": "to regulate", "normalized": "to regulate"}}, {"subject": {"text": "These properties of peptides", "keywords": [{"text": "peptides"}, {"text": "properties"}]}, "sentence": " These properties of peptides has aided in development of novel therapeutics and is expected to drive growth of the market in the near future.", "object": {"text": "aided in development of novel therapeutics", "keywords": [{"text": "therapeutics"}, {"text": "development"}, {"text": "novel"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "peptides", "keywords": [{"text": "peptides"}]}, "sentence": " These properties of peptides has aided in development of novel therapeutics and is expected to drive growth of the market in the near future.", "action": {"verb": {"text": "aid", "tense": "past"}, "text": "has aided", "normalized": "have aid"}}, {"subject": {"text": "These properties of peptides", "keywords": [{"text": "peptides"}, {"text": "properties"}]}, "sentence": " These properties of peptides has aided in development of novel therapeutics and is expected to drive growth of the market in the near future.", "object": {"text": "growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "is expected to drive", "normalized": "be expect to drive"}}, {"subject": {"text": "the key players", "keywords": [{"text": "key players"}]}, "sentence": " Key players in the Peptide Therapeutics in Metabolic Disorders Market: Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the key players operating in the market", "keywords": [{"text": "key players"}, {"text": "market"}]}, "sentence": " Key players in the Peptide Therapeutics in Metabolic Disorders Market: Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.", "object": {"text": "AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S", "keywords": [{"text": "Novo Nordisk A/S"}, {"text": "Rhythm Pharmaceuticals Inc."}, {"text": "Teva Pharmaceutical Industries"}, {"text": "Pharmaceuticals Co. Ltd."}], "entities": [{"type": "Company", "text": "Roche Ltd"}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "PolyPeptide Group"}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Bachem Holding AG"}, {"type": "Company", "text": "Takeda Pharmaceuticals Co. Ltd."}, {"type": "Company", "text": "Rhythm Pharmaceuticals Inc."}, {"type": "Company", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "peptide therapeutics in metabolic disorders market", "keywords": [{"text": "peptide therapeutics"}, {"text": "metabolic disorders market"}]}, "sentence": " Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into: Intravenous", "object": {"text": "segmented"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Diabetes mellitus", "relevance": 0.988196, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}, {"text": "Obesity", "relevance": 0.902794, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Insulin", "relevance": 0.886894, "dbpedia_resource": "http://dbpedia.org/resource/Insulin"}, {"text": "Pharmaceutical industry", "relevance": 0.811039, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Diabetes mellitus type 1", "relevance": 0.76904, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_1"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.764946, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Diabetes mellitus type 2", "relevance": 0.670693, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_2"}, {"text": "Protein", "relevance": 0.651942, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Hypoglycemia", "relevance": 0.637088, "dbpedia_resource": "http://dbpedia.org/resource/Hypoglycemia"}, {"text": "Nutrition", "relevance": 0.572697, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.569047, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Hormone", "relevance": 0.552411, "dbpedia_resource": "http://dbpedia.org/resource/Hormone"}, {"text": "Metabolism", "relevance": 0.532128, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Genentech", "relevance": 0.506632, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Insulin resistance", "relevance": 0.504778, "dbpedia_resource": "http://dbpedia.org/resource/Insulin_resistance"}, {"text": "Amino acid", "relevance": 0.486359, "dbpedia_resource": "http://dbpedia.org/resource/Amino_acid"}, {"text": "InnoMed PredTox", "relevance": 0.461453, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Novo Nordisk", "relevance": 0.445026, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}], "categories": [{"score": 0.980992, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "partOf", "sentence": "Press release from: Coherent Market Insights - Pharmaceutical Industry Peptide Therapeutics in Metabolic Disorders Peptide therapeutics, due to their various advantages such as high stability, selectivity, safety, efficacy, bioavailability, and tolerability offers wide applications over the other therapeutics classes.", "score": 0.751791, "arguments": [{"text": "Pharmaceutical Industry Peptide Therapeutics", "location": [47, 91], "entities": [{"type": "Organization", "text": "Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics"}]}, {"text": "Metabolic Disorders Peptide therapeutics", "location": [95, 135], "entities": [{"type": "Organization", "text": "Metabolic Disorders Peptide therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight.", "score": 0.297982, "arguments": [{"text": "adults", "location": [1559, 1565], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "1.9 billion", "location": [1547, 1558], "entities": [{"type": "Money", "text": "1.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight.", "score": 0.869285, "arguments": [{"text": "adults", "location": [1559, 1565], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "18 year", "location": [1567, 1574], "entities": [{"type": "Age", "text": "18 year"}]}]}, {"type": "hasAttribute", "sentence": "In rare cases, patients which are monogenic having single gene mutation which can lead to diabetes.", "score": 0.600426, "arguments": [{"text": "patients", "location": [1932, 1940], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diabetes", "location": [2007, 2015], "entities": [{"type": "HealthCondition", "text": "Diabetes mellitus"}]}]}, {"type": "partOf", "sentence": "Key players in the Peptide Therapeutics in Metabolic Disorders Market: Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S. Request For Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into: Intravenous", "score": 0.764786, "arguments": [{"text": "Peptide Therapeutics", "location": [2675, 2695], "entities": [{"type": "Organization", "text": "Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics"}]}, {"text": "Metabolic Disorders Market", "location": [2699, 2725], "entities": [{"type": "Organization", "text": "Metabolic Disorders Market Taxonomy On"}]}]}, {"type": "agentOf", "sentence": "Key players in the Peptide Therapeutics in Metabolic Disorders Market: Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S. Request For Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into: Intravenous", "score": 0.984609, "arguments": [{"text": "Novo Nordisk A/S.", "location": [3010, 3027], "entities": [{"type": "Organization", "text": "Novo Nordisk A/S.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Request", "location": [3028, 3035], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "partOf", "sentence": "Key players in the Peptide Therapeutics in Metabolic Disorders Market: Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S. Request For Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into: Intravenous", "score": 0.590566, "arguments": [{"text": "Metabolic Disorders Market Taxonomy On", "location": [3181, 3219], "entities": [{"type": "Organization", "text": "Metabolic Disorders Market Taxonomy On"}]}, {"text": "Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics", "location": [3040, 3177], "entities": [{"type": "Organization", "text": "Customization Of This Business Research Report : www.coherentmarketinsights.com/insight/request-customizat... Global Peptide Therapeutics"}]}]}, {"type": "locatedAt", "sentence": "Download PDF Brochure of This Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/2003 Market Drivers Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies.", "score": 0.579123, "arguments": [{"text": "Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/", "location": [652, 730], "entities": [{"type": "Organization", "text": "Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/"}]}, {"text": "Market", "location": [735, 741], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "employedBy", "sentence": "Download PDF Brochure of This Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/2003 Market Drivers Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies.", "score": 0.42137, "arguments": [{"text": "Drivers", "location": [742, 749], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/", "location": [652, 730], "entities": [{"type": "Organization", "text": "Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/"}]}]}, {"type": "locatedAt", "sentence": "Download PDF Brochure of This Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/2003 Market Drivers Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies.", "score": 0.557264, "arguments": [{"text": "Drivers", "location": [742, 749], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "Market", "location": [735, 741], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "affiliatedWith", "sentence": "Download PDF Brochure of This Business Research Report : www.coherentmarketinsights.com/insight/request-pdf/2003 Market Drivers Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies.", "score": 0.277626, "arguments": [{"text": "Manufacturers", "location": [750, 763], "entities": [{"type": "Organization", "text": "Manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Drivers", "location": [742, 749], "entities": [{"type": "Person", "text": "Drivers"}]}]}, {"type": "locatedAt", "sentence": "According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials.", "score": 0.113336, "arguments": [{"text": "Drug", "location": [931, 935], "entities": [{"type": "Substance", "text": "Drug"}]}, {"text": "Discovery", "location": [936, 945], "entities": [{"type": "Vehicle", "text": "Discovery"}]}]}, {"type": "partOfMany", "sentence": "Rising incidence of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are expected to be factors driving growth of the market.", "score": 0.554356, "arguments": [{"text": "Diabetes mellitus", "location": [1194, 1211], "entities": [{"type": "HealthCondition", "text": "Diabetes mellitus"}]}, {"text": "metabolic diseases", "location": [1167, 1185], "entities": [{"type": "HealthCondition", "text": "metabolic diseases"}]}]}, {"type": "employedBy", "sentence": "According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014.", "score": 0.495388, "arguments": [{"text": "WHO", "location": [1335, 1338], "entities": [{"type": "Person", "text": "WHO"}]}, {"text": "World Health Organization", "location": [1308, 1333], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "hasAttribute", "sentence": "According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014.", "score": 0.77903, "arguments": [{"text": "people", "location": [1371, 1377], "entities": [{"type": "Person", "text": "people"}]}, {"text": "diabetes", "location": [1393, 1401], "entities": [{"type": "HealthCondition", "text": "Diabetes mellitus"}]}]}], "keywords": [{"text": "peptide therapeutics", "sentiment": {"score": -0.391688, "label": "negative"}, "relevance": 0.97624}, {"text": "metabolic disorders", "sentiment": {"score": -0.451836, "label": "negative"}, "relevance": 0.797326}, {"text": "metabolic disorders market", "sentiment": {"score": -0.41591, "label": "negative"}, "relevance": 0.755647}, {"text": "Disorders Peptide therapeutics", "sentiment": {"score": -0.267661, "label": "negative"}, "relevance": 0.67432}, {"text": "Industry Peptide Therapeutics", "sentiment": {"score": -0.267661, "label": "negative"}, "relevance": 0.661005}, {"text": "Global Peptide Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593247}, {"text": "Business Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533429}, {"text": "metabolic diseases", "sentiment": {"score": -0.627686, "label": "negative"}, "relevance": 0.50608}, {"text": "therapeutics classes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492287}, {"text": "naturally occurring peptides", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464644}, {"text": "Coherent Market Insights", "sentiment": {"score": -0.378869, "label": "negative"}, "relevance": 0.458143}, {"text": "novel therapeutics", "sentiment": {"score": 0.545509, "label": "positive"}, "relevance": 0.455459}, {"text": "important peptide", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446755}, {"text": "www.coherentmarketinsights.com/insight/request-pdf/2003 Market Drivers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446393}, {"text": "Disorders Market Taxonomy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437617}, {"text": "Download PDF Brochure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423586}, {"text": "World Health Organization", "sentiment": {"score": 0.41356, "label": "positive"}, "relevance": 0.421998}, {"text": "world obesity rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421639}, {"text": "high incidence rate", "sentiment": {"score": -0.62535, "label": "negative"}, "relevance": 0.421026}, {"text": "glucose dependent action", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418437}, {"text": "Teva Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414036}, {"text": "Takeda Pharmaceuticals Co.", "sentiment": {"score": -0.220934, "label": "negative"}, "relevance": 0.413818}, {"text": "Novo Nordisk A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413105}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409502}, {"text": "Rhythm Pharmaceuticals Inc.", "sentiment": {"score": -0.500424, "label": "negative"}, "relevance": 0.40772}, {"text": "Bachem Holding AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402795}, {"text": "key players", "sentiment": {"score": -0.343332, "label": "negative"}, "relevance": 0.401767}, {"text": "biopharmaceutical peptides", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.397826}, {"text": "glucagon level", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379507}, {"text": "growth factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379143}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375051}, {"text": "tolerability offers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374487}, {"text": "wide applications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374457}, {"text": "high stability", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373628}, {"text": "various advantages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372952}, {"text": "ion channel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372293}, {"text": "crucial roles", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37225}, {"text": "human physiology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370662}, {"text": "Drug Discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367998}, {"text": "clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367771}, {"text": "glucose level", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367708}, {"text": "lispro insulin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366987}, {"text": "novel analogues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.365993}, {"text": "number people", "sentiment": {"score": -0.582861, "label": "negative"}, "relevance": 0.365937}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364131}, {"text": "data findings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364076}, {"text": "Ipsen S.A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363363}, {"text": "rare cases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363201}, {"text": "PolyPeptide Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362155}, {"text": "multiple genes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.361892}]}, "extracted_metadata": {"sha1": "399519a49c0fbd447dfd378b6c50ea4f662b6d74", "filename": "1541780729517.zip-839eb8c2c90bbc8685cefa004a6b1cfb.xml", "file_type": "json"}, "external_links": ["https://www.coherentmarketinsights.com/insight/request-pdf/2003", "https://www.coherentmarketinsights.com/insight/request-customization/2003"], "title": "Peptide Therapeutics In Metabolic Disorders Market To Show Significant Growth Over The Forecast Period 2018-2026 With key Vendors AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group", "forum_title": "openPR.com - New Public Relations: Health & Medicine"}, {"id": "d98xp-5qkPI1BobjtKvduJxpIrSPROXWAvDbVEXZ5lVFoL11kbSCxSzeLC-iGfE6", "result_metadata": {"score": 34.501286}, "author": "Seal Rock Therapeutics, Inc.", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Non-alcoholic fatty liver disease", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}], "categories": [{"score": 0.630798, "label": "/health and fitness/disease/cancer"}, {"score": 0.453057, "label": "/health and fitness/therapy"}, {"score": 0.414034, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "employedBy", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "score": 0.485089, "arguments": [{"text": "ASK1 Inhibitor", "location": [48, 62], "entities": [{"type": "Person", "text": "ASK1 Inhibitor"}]}, {"text": "Seal Rock Therapeutics Advancing Differentiated", "location": [0, 47], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}], "keywords": [{"text": "Differentiated ASK1 Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.96316}, {"text": "Seal Rock Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.869618}, {"text": "Lead Candidate S-015", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.715194}, {"text": "Nonalcoholic Steatohepatitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620981}]}, "crawl_date": "2018-11-10T09:14:08Z", "url": "https://www.prnewswire.com/news-releases/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash-300747392.html", "host": "prnewswire.com", "text": "Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "main_image_url": "https://mma.prnewswire.com/media/782258/Seal_Rock_Therapeutics_Inc_Logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T13:00:00-06:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.342035, "label": "positive"}, "text": "Seal Rock Therapeutics", "relevance": 0.828594, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "relevance": 0.689095, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.621638, "label": "positive"}, "text": "SRT-015", "relevance": 0.625333, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.336538, "label": "positive"}, "text": "Seal Rock Therapeutics, Inc.", "relevance": 0.5365, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer of Seal Rock Therapeutics", "relevance": 0.511017, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.405581, "label": "negative"}, "text": "NASH", "relevance": 0.438797, "type": "Person"}, {"count": 3, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Neil McDonnell", "relevance": 0.409246, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.422937, "label": "negative"}, "text": "fatty liver", "relevance": 0.404268, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}, {"count": 1, "sentiment": {"score": -0.337896, "label": "negative"}, "text": "non-alcoholic fatty liver disease", "relevance": 0.399054, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}, {"count": 2, "sentiment": {"score": -0.520894, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.398603, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "director", "relevance": 0.366437, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Takeda", "relevance": 0.356387, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock", "relevance": 0.350111, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna Therapeutics", "relevance": 0.340379, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.568746, "label": "negative"}, "text": "fibrotic diseases", "relevance": 0.337474, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pathway Therapeutics", "relevance": 0.331386, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver fibrosis", "relevance": 0.327836, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 2, "sentiment": {"score": -0.0889629, "label": "negative"}, "text": "SEATTLE", "relevance": 0.322361, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kathleen Elias", "relevance": 0.31185, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.499214, "label": "negative"}, "text": "metabolic disease", "relevance": 0.306697, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Business Development", "relevance": 0.302034, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Brown", "relevance": 0.299804, "type": "Person", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Artur Plonowski", "relevance": 0.299561, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Exelixis", "relevance": 0.297196, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Julie Rathbun Rathbun Communications", "relevance": 0.291313, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Research & Translational Medicine", "relevance": 0.288837, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "senior vice president", "relevance": 0.288309, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Keystone Symposia Integrated Pathways of Disease", "relevance": 0.286784, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.274629, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "vice president", "relevance": 0.268963, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.371387, "label": "positive"}, "text": "New Mexico", "relevance": 0.261069, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}, {"count": 1, "sentiment": {"score": -0.580282, "label": "negative"}, "text": "obesity", "relevance": 0.259146, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.258141, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0.310571, "label": "positive"}, "text": "Santa Fe", "relevance": 0.256757, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "diabetes", "relevance": 0.25613, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 2, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "Terry Porter", "relevance": 0.255233, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "managing director", "relevance": 0.254835, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.248206, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan", "relevance": 0.246582, "type": "Company", "disambiguation": {"subtype": [], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatocellular carcinoma", "relevance": 0.24565, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Scientific Officer", "relevance": 0.243742, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna", "relevance": 0.236286, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cytokinetics", "relevance": 0.23571, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.23308, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatomegaly", "relevance": 0.225847, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pioglitazone", "relevance": 0.224891, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "metformin", "relevance": 0.223538, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Metacrine", "relevance": 0.221463, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "CEO", "relevance": 0.220961, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazano", "relevance": 0.220094, "type": "Person"}], "sentiment": {"document": {"score": -0.14083, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a discovery stage company", "keywords": [{"text": "discovery stage company"}]}, "sentence": "SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "best-in-class treatments", "keywords": [{"text": "best-in-class treatments"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies,", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "discovery stage company"}, {"text": "best-in-class treatments"}, {"text": "available therapies"}], "entities": [{"type": "Location", "text": "SEATTLE", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Seal Rock Therapeutics, Inc."}, {"type": "HealthCondition", "text": "fibrotic diseases"}]}, "sentence": "SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued", "keywords": [{"text": "preclinical proof-of-concept findings"}, {"text": "differentiated inhibitor"}, {"text": "recent worldwide patent"}, {"text": "nonalcoholic steatohepatitis"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}]}, "sentence": " SRT-015 is a potent, liver-selective ASK1 inhibitor for NASH.", "object": {"text": "a potent, liver-selective ASK1 inhibitor for NASH", "keywords": [{"text": "liver-selective ASK1 inhibitor"}, {"text": "NASH"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "action": {"verb": {"text": "optimize", "tense": "past"}, "text": "was internally discovered and optimized", "normalized": "be internally discover and optimize"}}, {"subject": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities demonstrated by other investigative approaches", "keywords": [{"text": "investigative approaches"}, {"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "avoid", "tense": "present"}, "text": "avoid", "normalized": "avoid"}}, {"subject": {"text": "by other investigative approaches", "keywords": [{"text": "investigative approaches"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities", "keywords": [{"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}, {"text": "Gubra"}, {"text": "model"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "efficacy", "keywords": [{"text": "efficacy"}]}, "action": {"verb": {"text": "promise", "tense": "present"}, "text": "has demonstrated promising", "normalized": "have demonstrate promise"}}, {"subject": {"text": "statistically significant positive effects on both metabolic parameters and liver-specific pathology", "keywords": [{"text": "significant positive effects"}, {"text": "metabolic parameters"}, {"text": "liver-specific pathology"}]}, "sentence": " This includes statistically significant positive effects on both metabolic parameters and liver-specific pathology.", "object": {"text": "This"}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " In addition, SRT-015 significantly reduced hepatomegaly, liver fibrosis, steatosis and inflammation, all key drivers for NASH.", "object": {"text": "hepatomegaly, liver fibrosis, steatosis and inflammation", "keywords": [{"text": "liver fibrosis"}, {"text": "steatosis"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "hepatomegaly"}, {"type": "HealthCondition", "text": "liver fibrosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "object": {"text": "presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019", "keywords": [{"text": "Keystone Symposia Integrated"}, {"text": "Santa Fe"}, {"text": "NAFLD meeting"}, {"text": "New Mexico"}], "entities": [{"type": "PrintMedia", "text": "Keystone Symposia Integrated Pathways of Disease"}, {"type": "Location", "text": "Santa Fe", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"type": "Location", "text": "New Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a unique property", "keywords": [{"text": "unique property"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "the circulation or other tissues", "keywords": [{"text": "circulation"}, {"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "reduce risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "other tissues", "keywords": [{"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "helps reduce", "normalized": "help reduce"}}, {"subject": {"text": "Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "Chief Executive Officer"}, {"text": "Neil McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "JobTitle", "text": "Chief Executive Officer of Seal Rock Therapeutics"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "Company", "text": "SRT-015"}, {"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "we"}, "sentence": " \"Our preclinical findings are proving very robust, and we are pleased to be advancing with IND-enabling activities for SRT-015.\"", "object": {"text": "advancing with IND-enabling activities for SRT-015", "keywords": [{"text": "IND-enabling activities"}, {"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "object": {"text": "the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof", "keywords": [{"text": "ASK1 inhibitor compounds"}, {"text": "international PCT patent"}, {"text": "publication"}, {"text": "application"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The Patent Cooperation Treaty (PCT)", "keywords": [{"text": "Patent Cooperation Treaty"}, {"text": "PCT"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "151 countries", "keywords": [{"text": "countries"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine", "keywords": [{"text": "Chief Scientific Officer"}, {"text": "Vice President Research"}, {"text": "Neil McDonnell"}, {"text": "Artur Plonowski"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "Person", "text": "Artur Plonowski"}, {"type": "JobTitle", "text": "Chief Scientific Officer"}, {"type": "Person", "text": "Kathleen Elias"}, {"type": "JobTitle", "text": "Vice President Research & Translational Medicine"}]}, "sentence": " Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "object": {"text": "Seal Rock Therapeutics' founders", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "founders"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. McDonnell", "keywords": [{"text": "Dr. McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "object": {"text": "as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda", "keywords": [{"text": "senior vice president"}, {"text": "therapeutic area leader"}, {"text": "metabolic diseases"}, {"text": "Takeda"}], "entities": [{"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "Metacrine"}, {"type": "JobTitle", "text": "senior vice president"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin)", "keywords": [{"text": "diabetes drugs"}, {"text": "pioglitazone"}, {"text": "metformin"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "has been involved", "normalized": "have be involve"}}, {"subject": {"text": "Dr. Plonowski", "keywords": [{"text": "Dr. Plonowski"}], "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones", "keywords": [{"text": "NASH start-up"}, {"text": "Akarna Therapeutics"}, {"text": "Allergan"}, {"text": "pharmacology"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Akarna Therapeutics"}, {"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"type": "Quantity", "text": "$50 million"}, {"type": "Quantity", "text": "$1 billion"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "acquired by Allergan in 2016", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Allergan", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "was acquired", "normalized": "be acquire"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "object": {"text": "the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals,", "keywords": [{"text": "metabolic disease pharmacology"}, {"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "HealthCondition", "text": "metabolic disease", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "preclinical research"}, {"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}, {"text": "efforts"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry", "keywords": [{"text": "Senior Vice President"}, {"text": "Terry Porter"}, {"text": "Business Development"}, {"text": "PhD"}], "entities": [{"type": "Person", "text": "Terry Porter"}, {"type": "JobTitle", "text": "Senior Vice President, Business Development"}, {"type": "Person", "text": "David Brown", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"type": "JobTitle", "text": "director"}]}, "sentence": " Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "object": {"text": "Additional members of the Seal Rock leadership team", "keywords": [{"text": "Seal Rock leadership"}, {"text": "Additional members"}, {"text": "team"}], "entities": [{"type": "Organization", "text": "Seal Rock"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. Porter", "keywords": [{"text": "Dr. Porter"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "object": {"text": "as vice president of search & evaluation within global business development at Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "vice president"}, {"text": "global business development"}, {"text": "search"}], "entities": [{"type": "JobTitle", "text": "vice president"}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Prior to that, he was managing director at the corporate advisory group AquaPartners.", "object": {"text": "managing director at the corporate advisory group AquaPartners", "keywords": [{"text": "corporate advisory group"}, {"text": "director"}, {"text": "AquaPartners"}], "entities": [{"type": "JobTitle", "text": "managing director"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "action": {"verb": {"text": "create", "tense": "past"}, "text": "created", "normalized": "create"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "object": {"text": "the external science and technology group", "keywords": [{"text": "external science"}, {"text": "technology group"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Brown", "keywords": [{"text": "Dr."}], "entities": [{"type": "Person", "text": "David Brown"}]}, "sentence": " Dr. Brown recently directed the medicinal chemistry team at Pathway Therapeutics, which led to the selective PI3Kdelta kinase inhibitor PWT143/MEI-401.", "object": {"text": "the medicinal chemistry team", "keywords": [{"text": "medicinal chemistry team"}]}, "action": {"verb": {"text": "direct", "tense": "past"}, "text": "directed", "normalized": "direct"}}, {"subject": {"text": "he"}, "sentence": " Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "object": {"text": "12 years", "entities": [{"type": "Quantity", "text": "12 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "About NASH NASH", "keywords": [{"text": "NASH NASH"}]}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "a form of non-alcoholic fatty liver disease", "keywords": [{"text": "non-alcoholic fatty liver"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a form of non-alcoholic fatty liver disease (NAFLD)", "keywords": [{"text": "non-alcoholic fatty liver"}, {"text": "form"}, {"text": "disease"}, {"text": "NAFLD"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one of the most common chronic liver diseases", "keywords": [{"text": "common chronic liver"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "associated with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is associated", "normalized": "be associate"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "typically characterized as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "Fatty liver", "keywords": [{"text": "Fatty liver"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "sentence": " Fatty liver is generally non-progressive or progresses slowly compared to steatohepatitis.", "object": {"text": "generally non-progressive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.965998, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Fatty liver", "relevance": 0.942696, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.909327, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Patent Cooperation Treaty", "relevance": 0.754531, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Cooperation_Treaty"}, {"text": "Hepatitis", "relevance": 0.743176, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Obesity", "relevance": 0.624547, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Hepatology", "relevance": 0.624121, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Steatosis", "relevance": 0.492523, "dbpedia_resource": "http://dbpedia.org/resource/Steatosis"}, {"text": "Liver", "relevance": 0.472576, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Pharmacology", "relevance": 0.463799, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Cancer", "relevance": 0.463474, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Metabolic syndrome", "relevance": 0.456868, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Inborn error of metabolism", "relevance": 0.423532, "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}, {"text": "Hepatocellular carcinoma", "relevance": 0.416094, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Liver disease", "relevance": 0.408103, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Liver transplantation", "relevance": 0.404852, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Medicine", "relevance": 0.396867, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Hepatitis C", "relevance": 0.394926, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Patent", "relevance": 0.394174, "dbpedia_resource": "http://dbpedia.org/resource/Patent"}, {"text": "Drug discovery", "relevance": 0.383189, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Vice President of the United States", "relevance": 0.382542, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Metformin", "relevance": 0.377713, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Metabolism", "relevance": 0.377028, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Steatohepatitis", "relevance": 0.370723, "dbpedia_resource": "http://dbpedia.org/resource/Steatohepatitis"}, {"text": "Chronic liver disease", "relevance": 0.352756, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_liver_disease"}, {"text": "Patent law", "relevance": 0.351361, "dbpedia_resource": "http://dbpedia.org/resource/Patent_law"}, {"text": "Patent application", "relevance": 0.336226, "dbpedia_resource": "http://dbpedia.org/resource/Patent_application"}, {"text": "Drug design", "relevance": 0.332366, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Hepatitis B", "relevance": 0.324062, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Management occupations", "relevance": 0.312184, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Gastroenterology", "relevance": 0.31148, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Drug development", "relevance": 0.311191, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Pre-clinical development", "relevance": 0.310306, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Liver biopsy", "relevance": 0.306823, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Chief executive officer", "relevance": 0.306648, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Therapy", "relevance": 0.306567, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Enzyme inhibitor", "relevance": 0.28396, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Classification of Pharmaco-Therapeutic Referrals", "relevance": 0.272076, "dbpedia_resource": "http://dbpedia.org/resource/Classification_of_Pharmaco-Therapeutic_Referrals"}, {"text": "Medicinal chemistry", "relevance": 0.264488, "dbpedia_resource": "http://dbpedia.org/resource/Medicinal_chemistry"}, {"text": "Paris Convention for the Protection of Industrial Property", "relevance": 0.256971, "dbpedia_resource": "http://dbpedia.org/resource/Paris_Convention_for_the_Protection_of_Industrial_Property"}, {"text": "President of the United States", "relevance": 0.256336, "dbpedia_resource": "http://dbpedia.org/resource/President_of_the_United_States"}, {"text": "Richard Nixon", "relevance": 0.255099, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.254738, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.248341, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "John Adams", "relevance": 0.24366, "dbpedia_resource": "http://dbpedia.org/resource/John_Adams"}, {"text": "Vice president", "relevance": 0.241676, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Patent Law Treaty", "relevance": 0.237623, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Law_Treaty"}, {"text": "Lactic acidosis", "relevance": 0.235514, "dbpedia_resource": "http://dbpedia.org/resource/Lactic_acidosis"}, {"text": "Gerald Ford", "relevance": 0.234374, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}, {"text": "ASK1", "relevance": 0.231356, "dbpedia_resource": "http://dbpedia.org/resource/ASK1"}], "categories": [{"score": 0.687259, "label": "/health and fitness/disease"}, {"score": 0.422339, "label": "/health and fitness/therapy"}, {"score": 0.383633, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "timeOf", "sentence": "SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.877161, "arguments": [{"text": "today", "location": [178, 183], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [184, 193], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "managerOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.577847, "arguments": [{"text": "Chief Executive Officer", "location": [1524, 1547], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "Seal Rock Therapeutics", "location": [1551, 1573], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "\" Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "score": 0.994464, "arguments": [{"text": "Seal Rock Therapeutics", "location": [1718, 1740], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [1741, 1750], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "score": 0.40795, "arguments": [{"text": "founders", "location": [2060, 2068], "entities": [{"type": "Person", "text": "founders"}]}, {"text": "Seal Rock Therapeutics", "location": [2036, 2058], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.300954, "arguments": [{"text": "leader", "location": [2331, 2337], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "area", "location": [2326, 2330], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "hasAttribute", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.580563, "arguments": [{"text": "leader", "location": [2331, 2337], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "cardiovascular", "location": [2342, 2356], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "employedBy", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.799635, "arguments": [{"text": "leader", "location": [2331, 2337], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "Takeda", "location": [2383, 2389], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "score": 0.758695, "arguments": [{"text": "partner", "location": [2560, 2567], "entities": [{"type": "Person", "text": "Orexigen"}]}, {"text": "Takeda", "location": [2551, 2557], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.528062, "arguments": [{"text": "director of pharmacology", "location": [2665, 2689], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "Akarna Therapeutics", "location": [2693, 2712], "entities": [{"type": "Organization", "text": "Akarna Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.474504, "arguments": [{"text": "Allergan", "location": [2756, 2764], "entities": [{"type": "Organization", "text": "Allergan"}]}, {"text": "acquired", "location": [2744, 2752], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.97932, "arguments": [{"text": "2016", "location": [2768, 2772], "entities": [{"type": "Date", "text": "2016"}]}, {"text": "acquired", "location": [2744, 2752], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.358936, "arguments": [{"text": "its", "location": [194, 197], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "announced", "location": [184, 193], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.802833, "arguments": [{"text": "he", "location": [2836, 2838], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "cardiovascular", "location": [2847, 2861], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.489941, "arguments": [{"text": "he", "location": [2836, 2838], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "metabolic disease", "location": [2873, 2890], "entities": [{"type": "HealthCondition", "text": "metabolic diseases"}]}]}, {"type": "partOf", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.849637, "arguments": [{"text": "pharmacology group", "location": [2891, 2909], "entities": [{"type": "Organization", "text": "Business Development"}]}, {"text": "Takeda Pharmaceuticals", "location": [2913, 2935], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "score": 0.74674, "arguments": [{"text": "director of preclinical research", "location": [3123, 3155], "entities": [{"type": "Person", "text": "Elias"}]}, {"text": "Takeda", "location": [3159, 3165], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "score": 0.763089, "arguments": [{"text": "she", "location": [3328, 3331], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "heart failure", "location": [3453, 3466], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "partOfMany", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.79386, "arguments": [{"text": "members", "location": [3560, 3567], "entities": [{"type": "Person", "text": "members"}]}, {"text": "leadership team", "location": [3585, 3600], "entities": [{"type": "Person", "text": "leadership team"}]}]}, {"type": "employedBy", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.365905, "arguments": [{"text": "leadership team", "location": [3585, 3600], "entities": [{"type": "Person", "text": "leadership team"}]}, {"text": "Seal Rock", "location": [3575, 3584], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.67597, "arguments": [{"text": "David Brown", "location": [3678, 3689], "entities": [{"type": "Person", "text": "David Brown"}]}, {"text": "PhD", "location": [3692, 3695], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "employedBy", "sentence": "Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "score": 0.571629, "arguments": [{"text": "vice president", "location": [3750, 3764], "entities": [{"type": "Person", "text": "Terry Porter"}]}, {"text": "Takeda Pharmaceuticals", "location": [3826, 3848], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, he was managing director at the corporate advisory group AquaPartners.", "score": 0.786842, "arguments": [{"text": "managing director", "location": [3872, 3889], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [3916, 3921], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "employedBy", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.477414, "arguments": [{"text": "member", "location": [3957, 3963], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [4002, 4007], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.592035, "arguments": [{"text": "Keystone Symposia Integrated Pathways", "location": [1098, 1135], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "meeting", "location": [1165, 1172], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "partOf", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.78002, "arguments": [{"text": "group", "location": [4002, 4007], "entities": [{"type": "Organization", "text": "AquaPartners"}]}, {"text": "GlaxoSmithKline", "location": [4011, 4026], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "score": 0.667072, "arguments": [{"text": "GSK", "location": [4145, 4148], "entities": [{"type": "Organization", "text": "GSK"}]}, {"text": "acquisition", "location": [4164, 4175], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "residesIn", "sentence": "Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "score": 0.421297, "arguments": [{"text": "candidates", "location": [4434, 4444], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "areas", "location": [4452, 4457], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "hasAttribute", "sentence": "About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "score": 0.608891, "arguments": [{"text": "NASH NASH", "location": [4494, 4503], "entities": [{"type": "Person", "text": "NASH NASH"}]}, {"text": "disease", "location": [4543, 4550], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "score": 0.790092, "arguments": [{"text": "NAFLD", "location": [4664, 4669], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "diabetes", "location": [4727, 4735], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "agentOf", "sentence": "NAFLD is typically characterized as either fatty liver or steatohepatitis.", "score": 0.969466, "arguments": [{"text": "NAFLD", "location": [4759, 4764], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "characterized", "location": [4778, 4791], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "agentOf", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.702372, "arguments": [{"text": "NASH", "location": [4925, 4929], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "characterized", "location": [4982, 4995], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "hasAttribute", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.561306, "arguments": [{"text": "individuals", "location": [5090, 5101], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "cirrhosis", "location": [5127, 5136], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.694633, "arguments": [{"text": "NASH", "location": [5210, 5214], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "liver transplantation", "location": [5256, 5277], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.676101, "arguments": [{"text": "women", "location": [5312, 5317], "entities": [{"type": "Person", "text": "women"}]}, {"text": "liver transplantation", "location": [5256, 5277], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "hasAttribute", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.658529, "arguments": [{"text": "NASH", "location": [1150, 1154], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Disease", "location": [1139, 1146], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "locatedAt", "sentence": "About Seal Rock Therapeutics Seal Rock Therapeutics is a privately held, discovery stage company based in Seattle focused on the development of best-in-class treatments for inflammatory and fibrotic diseases with no available therapies.", "score": 0.734803, "arguments": [{"text": "company", "location": [5514, 5521], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "Seattle", "location": [5531, 5538], "entities": [{"type": "GeopoliticalEntity", "text": "SEATTLE"}]}]}, {"type": "employedBy", "sentence": "The company's lead product candidate, SRT-015, is a differentiated ASK1 inhibitor for NASH.", "score": 0.408221, "arguments": [{"text": "candidate", "location": [5689, 5698], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "company", "location": [5666, 5673], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}]}, {"type": "hasAttribute", "sentence": "For more information, please visit www.sealrocktx.com Media Contact: Julie Rathbun Rathbun Communications Julie@rathbuncomm.com 206-769-9219 SOURCE Seal Rock Therapeutics, Inc. Related Links http://www.sealrocktx.com", "score": 0.671673, "arguments": [{"text": "SOURCE Seal Rock Therapeutics, Inc.\nRelated Links", "location": [6031, 6080], "entities": [{"type": "Organization", "text": "SOURCE Seal Rock Therapeutics, Inc.\nRelated Links"}]}, {"text": "http://www.sealrocktx.com", "location": [6081, 6106], "entities": [{"type": "Web", "text": "http://www.sealrocktx.com"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.67241, "arguments": [{"text": "NASH", "location": [1150, 1154], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "meeting", "location": [1165, 1172], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.960106, "arguments": [{"text": "NAFLD", "location": [1159, 1164], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "meeting", "location": [1165, 1172], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.854132, "arguments": [{"text": "meeting", "location": [1165, 1172], "entities": [{"type": "EventMeeting", "text": "meeting"}]}, {"text": "Santa Fe", "location": [1177, 1185], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.995901, "arguments": [{"text": "Santa Fe", "location": [1177, 1185], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}, {"text": "New Mexico", "location": [1187, 1197], "entities": [{"type": "GeopoliticalEntity", "text": "New Mexico"}]}]}, {"type": "agentOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.920089, "arguments": [{"text": "Neil McDonnell", "location": [1507, 1521], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "said", "location": [1502, 1506], "entities": [{"type": "EventCommunication", "text": "said"}]}]}], "keywords": [{"text": "Seal Rock Therapeutics", "sentiment": {"score": 0.339287, "label": "positive"}, "relevance": 0.977832}, {"text": "vice president", "sentiment": {"score": -0.535413, "label": "negative"}, "relevance": 0.55322}, {"text": "discovery stage company", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.548468}, {"text": "Rock Therapeutics Seal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546927}, {"text": "senior vice president", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.544857}, {"text": "Gubra therapeutic NASH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543055}, {"text": "ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.539838}, {"text": "NASH NASH", "sentiment": {"score": -0.337896, "label": "negative"}, "relevance": 0.53209}, {"text": "fatty liver", "sentiment": {"score": -0.380416, "label": "negative"}, "relevance": 0.525787}, {"text": "Seal Rock leadership", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514018}, {"text": "liver-selective ASK1 inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510682}, {"text": "SOURCE Seal Rock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507892}, {"text": "business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.505916}, {"text": "fatty liver disease", "sentiment": {"score": -0.337896, "label": "negative"}, "relevance": 0.504808}, {"text": "preclinical proof-of-concept findings", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.504196}, {"text": "PI3Kdelta kinase inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498746}, {"text": "chronic liver diseases", "sentiment": {"score": -0.694965, "label": "negative"}, "relevance": 0.498436}, {"text": "ASK1 inhibitor compounds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498024}, {"text": "preclinical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497453}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": -0.520894, "label": "negative"}, "relevance": 0.496506}, {"text": "metabolic disease pharmacology", "sentiment": {"score": -0.499214, "label": "negative"}, "relevance": 0.495387}, {"text": "worldwide patent application", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.492927}, {"text": "best-in-class treatments", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.489992}, {"text": "differentiated ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.489957}, {"text": "NASH start-up", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48893}, {"text": "inflammation therapeutic areas", "sentiment": {"score": -0.409165, "label": "negative"}, "relevance": 0.487455}, {"text": "Akarna Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487032}, {"text": "international PCT patent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484953}, {"text": "Vice President Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484931}, {"text": "Neil McDonnell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484283}, {"text": "worldwide business development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484282}, {"text": "global business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.481603}, {"text": "Pathway Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481}, {"text": "fibrotic diseases", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.480541}, {"text": "international patent law", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47995}, {"text": "therapeutic area leader", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.477644}, {"text": "available therapies", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.477572}, {"text": "obesity drug Contrave", "sentiment": {"score": -0.205465, "label": "negative"}, "relevance": 0.477491}, {"text": "myosin activator therapeutic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477411}, {"text": "Rathbun Rathbun Communications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47735}, {"text": "Patent Cooperation Treaty", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4768}, {"text": "drug development efforts", "sentiment": {"score": -0.486984, "label": "negative"}, "relevance": 0.476638}, {"text": "significant positive effects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47649}, {"text": "major pharmaceutical markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475669}, {"text": "Symposia Integrated Pathways", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475029}, {"text": "corporate advisory group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474323}, {"text": "liver fibrosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473531}, {"text": "differentiated inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472577}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471265}, {"text": "Chief Scientific Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470241}]}, "extracted_metadata": {"sha1": "3f4e9903a74781899be8f6b2e6cd4d7d73b4696a", "filename": "1541841248776.zip-160bc615f0acf9bff3bef1914c03e1e7.xml", "file_type": "json"}, "external_links": ["http://www.sealrocktx.com/"], "title": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "forum_title": "All Clinical Trials &amp; Medical Discoveries News and Press Releases from PR Newswire"}, {"id": "FFf3igV6nS0K-4DZJm2TV0zes3-xBKmrtourcEIXlugz2dWiW9UeK8s5wdW1J6Hh", "result_metadata": {"score": 32.330227}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-09T15:09:31Z", "url": "https://www.businesswire.com/news/home/20181109005223/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T11:53:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.735789, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.703678, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.571664, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.558909, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.54551, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542596, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.517422, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512009, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.466607, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.450856, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,078,100 1.27%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,050,900 1.39%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,271,786 1.42%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,188,415 1.53%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "32,844,286 4.13%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,208,115 4.18%", "relevance": 0.450856, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.450856, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 32,844,286 4.13% 33,208,115 4.18% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "32,844,286 4.13"}, {"type": "Quantity", "text": "33,208,115 4.18"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,050,900 1.39% 12,188,415 1.53% (2) Cash-settled derivatives: 11,271,786 1.42% 10,078,100 1.27% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 32,844,286 4.13% 33,208,115 4.18% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "32,844,286 4.13% 33,208,115 4.18% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "32,844,286 4.13"}, {"type": "Quantity", "text": "33,208,115 4.18"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,050,900 1.39% 12,188,415 1.53% (2) Cash-settled derivatives: 11,271,786 1.42% 10,078,100 1.27% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 32,844,286 4.13% 33,208,115 4.18% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 9 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659082 Time of Receipt (offset from UTC): 20181109T111440+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.988606, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.774105, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.708548, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.61408, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.593352, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.434876, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.402248, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.386495, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Options", "relevance": 0.384522, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Security", "relevance": 0.355002, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "December", "relevance": 0.333335, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Contract", "relevance": 0.330751, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.329856, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}], "categories": [{"score": 0.568912, "label": "/real estate/buying and selling homes"}, {"score": 0.470703, "label": "/finance/financial news"}, {"score": 0.460063, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 71 4,624.5375 JPY Ordinary NPV SWAP Long 75 4,630.0369 JPY Ordinary NPV SWAP Long 185 4,630.9692 JPY Ordinary NPV SWAP Long 188 4,636.8362 JPY Ordinary NPV SWAP Long 220 4,629.2817 JPY Ordinary NPV SWAP Long 400 4,622.2942 JPY Ordinary NPV SWAP Long 547 4,625.4251 JPY Ordinary NPV SWAP Long 561 4,629.6464 JPY Ordinary NPV SWAP Long 775 4,624.4884 JPY Ordinary NPV SWAP Long 2,561 4,622.7539 JPY Ordinary NPV SWAP Long 2,717 4,622.7524 JPY Ordinary NPV SWAP Short 600 4,623.2500 JPY Ordinary NPV CFD Short 1,300 4,679.4676 JPY Ordinary NPV CFD Short 10,000 4,605.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing,", "score": 0.682599, "arguments": [{"text": "i", "location": [6284, 6285], "entities": [{"type": "Person", "text": "JPY Ordinary NPV SWAP Short"}]}, {"text": "Writing", "location": [6287, 6294], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7258, 7264], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7275, 7282], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 9 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8183, 8189], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8197, 8201], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [8629, 8635], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8643, 8656], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8264, 8288], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8256, 8261], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10775, 10799], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10767, 10772], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8423, 8428], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8442, 8469], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10934, 10939], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10953, 10980], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8705, 8711], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8737, 8749], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659082 Time of Receipt (offset from UTC): 20181109T111440+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [11080, 11083], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [11059, 11066], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.955643}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636842}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516637}, {"text": "561 4,629.6471 JPY Ordinary NPV Sale 600 4,613.8333 JPY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505931}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371315}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338823}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291681}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.286133}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.284873}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.283353}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.255005}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237678}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234314}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.227676}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226023}]}, "extracted_metadata": {"sha1": "198a7b2de8c33a9c6f3601052cc99a4941a8b632", "filename": "1541776171132.zip-7d278d889338c0aa60f52bfcb9a9d525.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "iuz6TkhK8t4772AiGl_gstvUIvXFzELohr8knoEXLC8KTz0ibUQqFWFnCAMVVf4j", "result_metadata": {"score": 32.294353}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL COMPANY LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.501679, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.499208, "label": "/business and industrial/company/earnings"}, {"score": 0.499114, "label": "/finance/investing"}], "relations": [], "keywords": [{"text": "Adage Capital Prtnrs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.920672}, {"text": "TAKEDA PHARMACEUTICAL COMPANY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.850205}]}, "crawl_date": "2018-11-10T00:34:32Z", "url": "https://www.moneyam.com/action/news/showArticle?id=6202249", "host": "moneyam.com", "text": "., which is the legal owner of the stock) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T18:16:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adage Capital Partners GP", "relevance": 0.966166, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adage Capital Partners", "relevance": 0.656655, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL COMPANY LTD", "relevance": 0.333415, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.272211, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.267172, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "general partner", "relevance": 0.264501, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "L.P.", "relevance": 0.223042, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.921004, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Offer and acceptance", "relevance": 0.88812, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}], "categories": [{"score": 0.525836, "label": "/finance/investing/funds/hedge fund"}, {"score": 0.490128, "label": "/finance/investing/beginning investing"}, {"score": 0.48402, "label": "/finance/financial news"}], "relations": [{"type": "partOf", "sentence": "(a) Identity of the person whose positions/dealings are being disclosed: Adage Capital Partners GP, L.L.C. (Adage Capital Partners GP, L.L.C. is the general partner of Adage Capital Partners, L.P., which is the legal owner of the stock) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree TAKEDA PHARMACEUTICAL COMPANY LTD (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 9 November 2018 (f)", "score": 0.390178, "arguments": [{"text": "general partner", "location": [149, 164], "entities": [{"type": "Organization", "text": "general partner"}]}, {"text": "Adage Capital Partners, L.P.", "location": [168, 196], "entities": [{"type": "Organization", "text": "Adage Capital Partners, L.P.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "score": 0.83624, "arguments": [{"text": "they", "location": [782, 786], "entities": [{"type": "Person", "text": "they"}]}, {"text": "disclosing", "location": [793, 803], "entities": [{"type": "EventCommunication", "text": "disclosing"}]}]}, {"type": "timeOf", "sentence": "Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "score": 0.716052, "arguments": [{"text": "today", "location": [787, 792], "entities": [{"type": "Date", "text": "today"}]}, {"text": "disclosing", "location": [793, 803], "entities": [{"type": "EventCommunication", "text": "disclosing"}]}]}], "keywords": [{"text": "Adage Capital Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.98827}, {"text": "Capital Partners GP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.799918}, {"text": "TAKEDA PHARMACEUTICAL COMPANY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561927}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552582}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522488}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511923}, {"text": "general partner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394477}, {"text": "vehicle companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387807}, {"text": "legal owner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383816}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383473}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.382486}, {"text": "SHIRE PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376253}, {"text": "offeror/offeree", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.295196}, {"text": "disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.287041}, {"text": "person", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.269938}, {"text": "L.L.C.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257783}, {"text": "identity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256478}, {"text": "interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25411}, {"text": "nominee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250167}, {"text": "naming", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242116}, {"text": "controller", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241008}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237933}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237505}, {"text": "positions/dealings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233553}, {"text": "L.P.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233027}, {"text": "stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232832}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231448}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230981}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230747}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23063}]}, "extracted_metadata": {"sha1": "668022df045d116b4c237f19bd5806baea1deb1a", "filename": "1541810072903.zip-1c6eb4157e59ab2a54531bb4f99dea52.xml", "file_type": "json"}, "title": "Adage Capital Prtnrs Form 8.3 - TAKEDA PHARMACEUTICAL COMPANY LTD", "forum_title": "MoneyAM News"}, {"id": "7NaG7kMBkzwh1xglUM4sq5DjvQJ1IP-A5x8gsj2Vxu2hG5tdUClbpCXZy2gOfirq", "result_metadata": {"score": 31.806892}, "author": "mayor", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.523085, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.523085, "label": "positive"}, "text": "EU", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0.520968, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": "Exclusive: Takeda to win EU approval for $62 billion Shire deal \u2013 sources", "object": {"text": "EU approval", "keywords": [{"text": "EU approval"}], "entities": [{"type": "Organization", "text": "EU"}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "to win", "normalized": "to win"}}], "concepts": [{"text": "France", "relevance": 0.860492, "dbpedia_resource": "http://dbpedia.org/resource/France"}, {"text": "Microsoft", "relevance": 0.796359, "dbpedia_resource": "http://dbpedia.org/resource/Microsoft"}], "categories": [{"score": 0.517544, "label": "/finance/investing"}, {"score": 0.517544, "label": "/finance/investing/beginning investing"}, {"score": 0.464955, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "EU approval", "sentiment": {"score": 0.523085, "label": "positive"}, "relevance": 0.938336}, {"text": "Shire deal", "sentiment": {"score": 0.523085, "label": "positive"}, "relevance": 0.869536}, {"text": "Takeda", "sentiment": {"score": 0.523085, "label": "positive"}, "relevance": 0.669719}, {"text": "sources", "sentiment": {"score": 0.523085, "label": "positive"}, "relevance": 0.382819}]}, "crawl_date": "2018-11-09T19:43:33Z", "url": "https://www.oann.com/exclusive-eu-regulators-to-clear-62-billion-takeda-shire-deal-source/", "host": "oann.com", "text": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal \u2013 sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T18:55:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": 0.0554097, "label": "positive"}, "text": "Takeda", "relevance": 0.872601, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.556022, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.530105, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0.48963, "label": "positive"}, "text": "Foo Yun Chee", "relevance": 0.448199, "type": "Person"}, {"count": 3, "sentiment": {"score": 0.36723, "label": "positive"}, "text": "EU", "relevance": 0.391533, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": -0.6412, "label": "negative"}, "text": "Shire Plc", "relevance": 0.349906, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.334613, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London\u2019s Shire", "relevance": 0.329148, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.522828, "label": "negative"}, "text": "Shire", "relevance": 0.317313, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.299355, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 3, "sentiment": {"score": -0.6412, "label": "negative"}, "text": "Entyvio", "relevance": 0.271023, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.252956, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": -0.365536, "label": "negative"}, "text": "United States", "relevance": 0.238743, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.587771, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.237332, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.21559, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.207585, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BRUSSELS", "relevance": 0.205038, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"count": 1, "sentiment": {"score": 0.589684, "label": "positive"}, "text": "Elaine Hardcastle", "relevance": 0.183523, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.6412, "label": "negative"}, "text": "European Commission", "relevance": 0.181034, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.589684, "label": "positive"}, "text": "Susan Fenton", "relevance": 0.178426, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.155242, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.142667, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.28 percent", "relevance": 0.142667, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.142667, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62", "relevance": 0.142667, "type": "Quantity"}], "sentiment": {"document": {"score": 0.0238991, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal \u2013 sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "EU approval", "keywords": [{"text": "EU approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "to win", "normalized": "to win"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal \u2013 sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "seen at its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "new headquarters"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal \u2013 sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}, {"subject": {"text": "BRUSSELS (Reuters) \u2013 Japanese drugmaker Takeda Pharmaceutical <4502.T>", "keywords": [{"text": "Japanese drugmaker Takeda"}, {"text": "Reuters"}, {"text": "BRUSSELS"}, {"text": "Pharmaceutical"}], "entities": [{"type": "Location", "text": "BRUSSELS", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "CityTown", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"type": "Company", "text": "Reuters", "disambiguation": {"subtype": ["Company"], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " BRUSSELS (Reuters) \u2013 Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London\u2019s Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "to win conditional EU antitrust approval for its $62-billion bid for London\u2019s Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday", "keywords": [{"text": "EU antitrust approval"}, {"text": "overseas acquisition"}, {"text": "Japanese company"}, {"text": "bid"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Organization", "text": "London\u2019s Shire"}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "BRUSSELS (Reuters) \u2013 Japanese drugmaker Takeda Pharmaceutical <4502.T>", "keywords": [{"text": "Japanese drugmaker Takeda"}, {"text": "Reuters"}, {"text": "BRUSSELS"}, {"text": "Pharmaceutical"}], "entities": [{"type": "Location", "text": "BRUSSELS", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "CityTown", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"type": "Company", "text": "Reuters", "disambiguation": {"subtype": ["Company"], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " BRUSSELS (Reuters) \u2013 Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London\u2019s Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "is set to win", "normalized": "be set to win"}}, {"subject": {"text": "two people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "sentence": " BRUSSELS (Reuters) \u2013 Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London\u2019s Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "BRUSSELS (Reuters) \u2013 Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London\u2019s Shire, the biggest ever overseas acquisition by a Japanese company", "keywords": [{"text": "EU antitrust approval"}, {"text": "drugmaker Takeda Pharmaceutical"}, {"text": "overseas acquisition"}, {"text": "Japanese company"}], "entities": [{"type": "Location", "text": "BRUSSELS", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "CityTown", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"type": "Company", "text": "Reuters", "disambiguation": {"subtype": ["Company"], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Organization", "text": "London\u2019s Shire"}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc\u2019s pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "to divest Shire Plc\u2019s pipeline compound SHP647 along with some associated rights", "keywords": [{"text": "Shire Plc"}, {"text": "associated rights"}, {"text": "pipeline"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "offer", "tense": "past"}, "text": "offered", "normalized": "offer"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc\u2019s pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "Shire Plc\u2019s pipeline compound SHP647", "keywords": [{"text": "pipeline compound"}, {"text": "Shire Plc"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "offered to divest", "normalized": "offer to divest"}}, {"subject": {"text": "Shire Plc", "keywords": [{"text": "Plc"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " Last month, Takeda offered to divest Shire Plc\u2019s pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "pipeline compound SHP647 along with some associated rights", "keywords": [{"text": "pipeline compound SHP647"}, {"text": "associated rights"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc\u2019s pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "overlap"}, {"text": "concerns"}, {"text": "drug"}], "entities": [{"type": "Person", "text": "Entyvio"}]}, "action": {"verb": {"text": "voice", "tense": "past"}, "text": "voiced", "normalized": "voice"}}, {"subject": {"text": "Entyvio, a treatment for Crohn\u2019s disease and ulcerative colitis,", "keywords": [{"text": "ulcerative colitis"}, {"text": "Crohn\u2019s disease"}, {"text": "Entyvio"}, {"text": "treatment"}], "entities": [{"type": "Person", "text": "Entyvio"}, {"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Entyvio, a treatment for Crohn\u2019s disease and ulcerative colitis, is Takeda\u2019s biggest-selling drug.", "object": {"text": "Takeda\u2019s biggest-selling drug", "keywords": [{"text": "Takeda"}, {"text": "biggest-selling drug"}], "entities": [{"type": "Person", "text": "Entyvio"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}]}, "sentence": " Shire\u2019s shares moved into positive territory in London following the Reuters story, closing up 0.28 percent.", "object": {"text": "shares moved into positive territory in London", "keywords": [{"text": "positive territory"}, {"text": "shares"}, {"text": "London"}], "entities": [{"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Shire\u2019s shares", "keywords": [{"text": "Shire"}, {"text": "shares"}]}, "sentence": " Shire\u2019s shares moved into positive territory in London following the Reuters story, closing up 0.28 percent.", "object": {"text": "into positive territory", "keywords": [{"text": "positive territory"}]}, "action": {"verb": {"text": "move", "tense": "past"}, "text": "moved", "normalized": "move"}}, {"subject": {"text": "Its U.S. listed shares <SHPG.O>", "keywords": [{"text": "U.S."}, {"text": "shares"}, {"text": "SHPG.O"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Its U.S. listed shares <SHPG.O> recovered some earlier losses after the story.", "object": {"text": "some earlier losses", "keywords": [{"text": "earlier losses"}]}, "action": {"verb": {"text": "recover", "tense": "past"}, "text": "recovered", "normalized": "recover"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda is looking to the acquisition to boost its late-stage pipeline.", "object": {"text": "to the acquisition to boost its late-stage pipeline", "keywords": [{"text": "late-stage pipeline"}, {"text": "acquisition"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "is looking", "normalized": "be look"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda is looking to the acquisition to boost its late-stage pipeline.", "object": {"text": "its late-stage pipeline", "keywords": [{"text": "late-stage pipeline"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "Rare disease specialist Shire", "keywords": [{"text": "disease specialist Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "sentence": " Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "object": {"text": "seven drug candidates in Phase 3 clinical trials compared to its three", "keywords": [{"text": "drug candidates"}, {"text": "clinical trials"}, {"text": "Phase"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal would also make it a global top 10 drugmaker.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "would also make", "normalized": "would also make"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "scheduled to rule on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "to rule on the deal by Nov. 20", "keywords": [{"text": "deal"}, {"text": "Nov."}], "entities": []}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "rule", "tense": "future"}, "text": "is scheduled to rule", "normalized": "be schedule to rule"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire did not immediately respond to a request for comment.", "object": {"text": "not immediately respond to a request for comment", "keywords": [{"text": "comment"}, {"text": "request"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "did", "normalized": "do"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire did not immediately respond to a request for comment.", "object": {"text": "to a request for comment", "keywords": [{"text": "comment"}, {"text": "request"}]}, "action": {"verb": {"text": "respond", "tense": "past", "negated": true}, "text": "respond", "normalized": "respond"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured unconditional clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "unconditional clearance"}, {"text": "United States"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "unconditional clearance", "keywords": [{"text": "unconditional clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.951701, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "European Union", "relevance": 0.807089, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Commission", "relevance": 0.69092, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Crohn's disease", "relevance": 0.677617, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Inflammatory bowel disease", "relevance": 0.667678, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Japan", "relevance": 0.570226, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "United States", "relevance": 0.54493, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Brussels", "relevance": 0.521542, "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}, {"text": "Colonoscopy", "relevance": 0.456527, "dbpedia_resource": "http://dbpedia.org/resource/Colonoscopy"}, {"text": "German language", "relevance": 0.450963, "dbpedia_resource": "http://dbpedia.org/resource/German_language"}, {"text": "Biopsy", "relevance": 0.449062, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}, {"text": "European Council", "relevance": 0.448351, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}, {"text": "Inflammation", "relevance": 0.444633, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "European Parliament", "relevance": 0.441754, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "Pharmacology", "relevance": 0.441146, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Helminthic therapy", "relevance": 0.438119, "dbpedia_resource": "http://dbpedia.org/resource/Helminthic_therapy"}, {"text": "London", "relevance": 0.419882, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Gastroenterology", "relevance": 0.416084, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.408087, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Clinical trial", "relevance": 0.406241, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Belgium", "relevance": 0.401634, "dbpedia_resource": "http://dbpedia.org/resource/Belgium"}], "categories": [{"score": 0.640794, "label": "/health and fitness/disease"}, {"score": 0.478554, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.379193, "label": "/finance/financial news"}], "relations": [{"type": "ownerOf", "sentence": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.627474, "arguments": [{"text": "its", "location": [141, 144], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "headquarters", "location": [149, 161], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.574188, "arguments": [{"text": "Takeda", "location": [548, 554], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "compound", "location": [594, 602], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "employedBy", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.676579, "arguments": [{"text": "Shire Plc", "location": [573, 582], "entities": [{"type": "Person", "text": "Shire Plc"}]}, {"text": "pipeline", "location": [585, 593], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "ownerOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.395012, "arguments": [{"text": "pipeline", "location": [585, 593], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [594, 602], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "hasAttribute", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.711646, "arguments": [{"text": "SHP647", "location": [603, 609], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "inflammatory bowel disease", "location": [730, 756], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "agentOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.981533, "arguments": [{"text": "European Commission", "location": [654, 673], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "voiced", "location": [674, 680], "entities": [{"type": "EventCommunication", "text": "voiced"}]}]}, {"type": "hasAttribute", "sentence": "Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "score": 0.913236, "arguments": [{"text": "Crohn", "location": [798, 803], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [806, 813], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "score": 0.791143, "arguments": [{"text": "Crohn", "location": [798, 803], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "ulcerative colitis", "location": [818, 836], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "locatedAt", "sentence": "Shire's shares moved into positive territory in London following the Reuters story, closing up 0.28 percent.", "score": 0.702301, "arguments": [{"text": "territory", "location": [907, 916], "entities": [{"type": "GeopoliticalEntity", "text": "BRUSSELS"}]}, {"text": "London", "location": [920, 926], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "affectedBy", "sentence": "Takeda is looking to the acquisition to boost its late-stage pipeline.", "score": 0.576553, "arguments": [{"text": "its", "location": [1106, 1109], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "acquisition", "location": [1085, 1096], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "score": 0.454557, "arguments": [{"text": "specialist", "location": [1144, 1154], "entities": [{"type": "Person", "text": "Shire Plc"}]}, {"text": "disease", "location": [1136, 1143], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "locatedAt", "sentence": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.955258, "arguments": [{"text": "headquarters", "location": [149, 161], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [165, 170], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "populationOf", "sentence": "Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "score": 0.167088, "arguments": [{"text": "three", "location": [1230, 1235], "entities": [{"type": "Cardinal", "text": "three"}]}, {"text": "its", "location": [1226, 1229], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "locatedAt", "sentence": "Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "score": 0.580836, "arguments": [{"text": "regulators", "location": [1520, 1530], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "United States", "location": [1538, 1551], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "(Reporting by Foo Yun Chee; Editing by Elaine Hardcastle and Susan Fenton)", "score": 0.560311, "arguments": [{"text": "Foo Yun Chee", "location": [1592, 1604], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "Reporting", "location": [1579, 1588], "entities": [{"type": "EventCommunication", "text": "Reporting"}]}]}, {"type": "residesIn", "sentence": "(Reporting by Foo Yun Chee; Editing by Elaine Hardcastle and Susan Fenton)", "score": 0.65787, "arguments": [{"text": "Foo Yun Chee", "location": [1592, 1604], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "Editing", "location": [1606, 1613], "entities": [{"type": "GeopoliticalEntity", "text": "Editing"}]}]}, {"type": "locatedAt", "sentence": "Search for: Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.939628, "arguments": [{"text": "Tokyo", "location": [165, 170], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [172, 177], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo November 9, 2018 By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.610675, "arguments": [{"text": "Foo Yun Chee", "location": [247, 259], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "BRUSSELS", "location": [260, 268], "entities": [{"type": "GeopoliticalEntity", "text": "BRUSSELS"}]}]}, {"type": "employedBy", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo November 9, 2018 By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.425401, "arguments": [{"text": "drugmaker", "location": [290, 299], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Reuters", "location": [270, 277], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo November 9, 2018 By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.486651, "arguments": [{"text": "drugmaker", "location": [290, 299], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Japanese", "location": [281, 289], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo November 9, 2018 By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.973826, "arguments": [{"text": "company", "location": [475, 482], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [466, 474], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo November 9, 2018 By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.74795, "arguments": [{"text": "people", "location": [488, 494], "entities": [{"type": "Person", "text": "people"}]}, {"text": "said", "location": [520, 524], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo November 9, 2018 By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.987908, "arguments": [{"text": "Friday", "location": [528, 534], "entities": [{"type": "Date", "text": "Friday"}]}, {"text": "said", "location": [520, 524], "entities": [{"type": "EventCommunication", "text": "said"}]}]}], "keywords": [{"text": "Foo Yun Chee", "sentiment": {"score": 0.48963, "label": "positive"}, "relevance": 0.934355}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.877208}, {"text": "Japanese drugmaker Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.811664}, {"text": "disease specialist Shire", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.523774}, {"text": "EU antitrust approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.494158}, {"text": "REUTERS/Kim Kyung-Hoon/File Photo", "sentiment": {"score": 0.439013, "label": "positive"}, "relevance": 0.470338}, {"text": "Shire deal", "sentiment": {"score": 0.36723, "label": "positive"}, "relevance": 0.444346}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.6412, "label": "negative"}, "relevance": 0.433235}, {"text": "EU competition enforcer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431774}, {"text": "Shire Plc", "sentiment": {"score": -0.6412, "label": "negative"}, "relevance": 0.366076}, {"text": "EU approval", "sentiment": {"score": 0.36723, "label": "positive"}, "relevance": 0.320269}, {"text": "new headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258872}, {"text": "Reuters story", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250136}, {"text": "ulcerative colitis", "sentiment": {"score": -0.587771, "label": "negative"}, "relevance": 0.24909}, {"text": "late-stage pipeline", "sentiment": {"score": 0.745809, "label": "positive"}, "relevance": 0.248128}, {"text": "Elaine Hardcastle", "sentiment": {"score": 0.589684, "label": "positive"}, "relevance": 0.240513}, {"text": "unconditional clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236362}, {"text": "Crohn\u2019s disease", "sentiment": {"score": -0.587771, "label": "negative"}, "relevance": 0.234076}, {"text": "overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232117}, {"text": "associated rights", "sentiment": {"score": -0.6412, "label": "negative"}, "relevance": 0.230616}, {"text": "Japanese company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230416}, {"text": "European Commission", "sentiment": {"score": -0.6412, "label": "negative"}, "relevance": 0.230273}, {"text": "earlier losses", "sentiment": {"score": -0.365536, "label": "negative"}, "relevance": 0.22887}, {"text": "biggest-selling drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.22419}, {"text": "positive territory", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.221869}, {"text": "clinical trials", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.215132}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.215063}, {"text": "Susan Fenton", "sentiment": {"score": 0.589684, "label": "positive"}, "relevance": 0.214077}, {"text": "drug candidates", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.213837}]}, "extracted_metadata": {"sha1": "f7bdadc7615e1a59f7e104df9666c3bfb94b891a", "filename": "1541792613971.zip-d6beb9298c5479115c5c441b9a07c230.xml", "file_type": "json"}, "title": "Exclusive: Takeda to win EU approval for $62 billion Shire deal \u2013 sources", "forum_title": "One America News Network"}, {"id": "fbdp72XsRdXlVLwhNWHmbnlB1hwR8HUk0ZK7Kh0UCuImDfplVkrKn6YRDdDTE3uc", "result_metadata": {"score": 31.760513}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.542519, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "EU regulators", "keywords": [{"text": "EU regulators"}], "entities": [{"type": "Organization", "text": "EU"}]}, "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source", "object": {"text": "$62 billion Takeda, Shire deal - source", "keywords": [{"text": "Shire deal"}, {"text": "Takeda"}, {"text": "source"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "clear", "tense": "future"}, "text": "to clear", "normalized": "to clear"}}], "concepts": [{"text": "European Union", "relevance": 0.896, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}], "categories": [{"score": 0.512485, "label": "/finance/financial news"}, {"score": 0.493757, "label": "/finance/investing"}, {"score": 0.493757, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source", "score": 0.745337, "arguments": [{"text": "regulators", "location": [14, 24], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "EU", "location": [11, 13], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source", "score": 0.682476, "arguments": [{"text": "regulators", "location": [14, 24], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "62 billion", "location": [37, 47], "entities": [{"type": "Money", "text": "62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "EU regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.946053}, {"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858064}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.746226}, {"text": "source", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481403}]}, "crawl_date": "2018-11-09T17:02:56Z", "url": "https://www.channelnewsasia.com/news/business/exclusive--eu-regulators-to-clear-us-62-billion-takeda--shire-deal---source-10914674", "host": "channelnewsasia.com", "text": "FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "main_image_url": "http://www.channelnewsasia.com/image/10914670/16x9/991/557/1bbcecc5f498ca4925530e554f56db6/NO/file-photo--takeda-pharmaceutical-co-s-logo-is-seen-at-its-new-headquarters-in-tokyo-5.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T16:35:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0.370037, "label": "positive"}, "text": "Shire", "relevance": 0.852007, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.370037, "label": "positive"}, "text": "Takeda Pharmaceutical", "relevance": 0.845777, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.789774, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.370037, "label": "positive"}, "text": "EU", "relevance": 0.760718, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0.370037, "label": "positive"}, "text": "London peer Shire", "relevance": 0.610155, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.370037, "label": "positive"}, "text": "US", "relevance": 0.326797, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.281594, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.258305, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}], "sentiment": {"document": {"score": 0.757932, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "EU regulators", "keywords": [{"text": "EU regulators"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source", "object": {"text": "$62 billion Takeda, Shire deal - source", "keywords": [{"text": "Shire deal"}, {"text": "Takeda"}, {"text": "source"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "clear", "tense": "future"}, "text": "to clear", "normalized": "to clear"}}, {"subject": {"text": "EU regulators", "keywords": [{"text": "EU regulators"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source", "object": {"text": "$62 billion Takeda, Shire deal - source", "keywords": [{"text": "Shire deal"}, {"text": "Takeda"}, {"text": "source"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "clear", "tense": "future"}, "text": "to clear", "normalized": "to clear"}}, {"subject": {"text": "EU antitrust regulators", "keywords": [{"text": "EU antitrust regulators"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "object": {"text": "to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer", "keywords": [{"text": "Japanese drugmaker Takeda"}, {"text": "Pharmaceutical"}, {"text": "offer"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "EU antitrust regulators", "keywords": [{"text": "EU antitrust regulators"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "object": {"text": "$62-billion offer", "keywords": [{"text": "offer"}], "entities": [{"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "approve", "tense": "future"}, "text": "are set to approve", "normalized": "be set to approve"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "object": {"text": "a drug", "keywords": [{"text": "drug"}]}, "action": {"verb": {"text": "sell", "tense": "present"}, "text": "sells", "normalized": "sell"}}, {"subject": {"text": "it"}, "sentence": " EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "object": {"text": "a drug", "keywords": [{"text": "drug"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "seen at its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "new headquarters"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}], "concepts": [{"text": "Japan", "relevance": 0.933703, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "European Union", "relevance": 0.908172, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "London", "relevance": 0.631202, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5874, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Breaking news", "relevance": 0.586632, "dbpedia_resource": "http://dbpedia.org/resource/Breaking_news"}, {"text": "Drug", "relevance": 0.554878, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}], "categories": [{"score": 0.624023, "label": "/finance/financial news"}, {"score": 0.438222, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.435787, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "employedBy", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "score": 0.693972, "arguments": [{"text": "regulators", "location": [14, 24], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "EU", "location": [11, 13], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "score": 0.728569, "arguments": [{"text": "regulators", "location": [119, 129], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "EU", "location": [116, 118], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "score": 0.60728, "arguments": [{"text": "antitrust regulators", "location": [184, 204], "entities": [{"type": "Person", "text": "antitrust regulators"}]}, {"text": "EU", "location": [181, 183], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "score": 0.806339, "arguments": [{"text": "drugmaker", "location": [233, 242], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Japanese", "location": [224, 232], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source close breaking news Business Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's US$62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.", "score": 0.988039, "arguments": [{"text": "Friday", "location": [411, 417], "entities": [{"type": "Date", "text": "Friday"}]}, {"text": "said", "location": [403, 407], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.656061, "arguments": [{"text": "Takeda Pharmaceutical Co", "location": [431, 455], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "headquarters", "location": [482, 494], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "ownerOf", "sentence": "FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.611291, "arguments": [{"text": "its", "location": [474, 477], "entities": [{"type": "Organization", "text": "London peer Shire"}]}, {"text": "headquarters", "location": [482, 494], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.959824, "arguments": [{"text": "headquarters", "location": [482, 494], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [498, 503], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.967273, "arguments": [{"text": "Tokyo", "location": [498, 503], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [505, 510], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Japanese drugmaker Takeda", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.94552}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.940692}, {"text": "EU antitrust regulators", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.905923}, {"text": "EU regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.874424}, {"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.869534}, {"text": "London peer Shire", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.859565}, {"text": "news Business Exclusive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.804559}, {"text": "related media assets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.726986}, {"text": "REUTERS/Kim Kyung-Hoon/File Photo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.714347}, {"text": "source close", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.607048}, {"text": "new headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579241}, {"text": "Nov", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.44426}, {"text": "Friday", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437559}, {"text": "matter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436017}, {"text": "Tokyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43518}, {"text": "Click", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434522}, {"text": "person", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433167}, {"text": "offer", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.430841}, {"text": "condition", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.430671}, {"text": "development", "sentiment": {"score": 0.370037, "label": "positive"}, "relevance": 0.430416}, {"text": "logo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429371}, {"text": "gallery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.428892}]}, "extracted_metadata": {"sha1": "eac66d6f904375dc3ac3c138b2e8cc6e469d9f58", "filename": "1541782976796.zip-9312cf8fba7015f0e801dfd9c1a668a0.xml", "file_type": "json"}, "title": "Exclusive: EU regulators to clear US$62 billion Takeda, Shire deal - source", "forum_title": "Channel NewsAsia"}, {"id": "Nk4t1zOP5JAKuV-wI9nvJn3eMXDU0b5rC55jsAQI9AMGOk3qMpptkWpX7iPXWxza", "result_metadata": {"score": 31.615936}, "author": "Midwest Communications Inc.", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.436681, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.436681, "label": "positive"}, "text": "EU", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0.603373, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": "Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources | News | WKZO", "object": {"text": "EU approval", "keywords": [{"text": "EU approval"}], "entities": [{"type": "Organization", "text": "EU"}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "to win", "normalized": "to win"}}], "concepts": [{"text": "WWMT", "relevance": 0.858596, "dbpedia_resource": "http://dbpedia.org/resource/WWMT"}, {"text": "France", "relevance": 0.821379, "dbpedia_resource": "http://dbpedia.org/resource/France"}, {"text": "Microsoft", "relevance": 0.760161, "dbpedia_resource": "http://dbpedia.org/resource/Microsoft"}], "categories": [{"score": 0.512185, "label": "/finance/financial news"}, {"score": 0.507967, "label": "/news/national news"}, {"score": 0.479856, "label": "/business and industrial/business news"}], "relations": [], "keywords": [{"text": "EU approval", "sentiment": {"score": 0.436681, "label": "positive"}, "relevance": 0.9984}, {"text": "Shire deal", "sentiment": {"score": 0.436681, "label": "positive"}, "relevance": 0.946325}, {"text": "WKZO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.820453}, {"text": "Takeda", "sentiment": {"score": 0.436681, "label": "positive"}, "relevance": 0.798091}, {"text": "sources", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568988}, {"text": "News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568103}]}, "crawl_date": "2018-11-09T17:39:25Z", "url": "https://wkzo.com/news/articles/2018/nov/09/exclusive-eu-regulators-to-clear-62-billion-takeda-shire-deal-source/", "host": "wkzo.com", "text": "EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "main_image_url": "https://radiocms-images.us1.eldarioncloud.com/resize/1200/https://storage.googleapis.com/media.mwcradio.com/mimesis/2018-11/09/2018-11-09T163313Z_1_LYNXNPEEA81DU-OUSBS_RTROPTP_3_BUSINESS-US-SHIRE-M-A-TAKEDA-PHARMA-EU-EXCLUSIVE.JPG?upscale=False", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T00:00:00-05:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0.0702848, "label": "positive"}, "text": "Takeda", "relevance": 0.866121, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.485559, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.269622, "label": "positive"}, "text": "Takeda Pharmaceutical", "relevance": 0.435206, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0.48963, "label": "positive"}, "text": "Foo Yun Chee", "relevance": 0.361035, "type": "Person"}, {"count": 3, "sentiment": {"score": 0.342375, "label": "positive"}, "text": "EU", "relevance": 0.306464, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": -0.629599, "label": "negative"}, "text": "Shire Plc", "relevance": 0.256419, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.245971, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.522828, "label": "negative"}, "text": "Shire", "relevance": 0.234011, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.195559, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 3, "sentiment": {"score": -0.629599, "label": "negative"}, "text": "Entyvio", "relevance": 0.194831, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.168948, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": -0.586548, "label": "negative"}, "text": "Crohn's disease", "relevance": 0.161172, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BRUSSELS", "relevance": 0.1576, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"count": 1, "sentiment": {"score": -0.586548, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.157576, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.156068, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0.537029, "label": "positive"}, "text": "Elaine Hardcastle", "relevance": 0.154294, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.269622, "label": "positive"}, "text": "London", "relevance": 0.141003, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 1, "sentiment": {"score": -0.629599, "label": "negative"}, "text": "European Commission", "relevance": 0.138675, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.134531, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.12103, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.119334, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.119334, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62", "relevance": 0.119334, "type": "Quantity"}], "sentiment": {"document": {"score": 0.18965, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": "Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources Friday, November 09, 2018 11:33 a.m.", "object": {"text": "EU approval", "keywords": [{"text": "EU approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "to win", "normalized": "to win"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "seen at its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "new headquarters"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}, {"subject": {"text": "Japanese drugmaker Takeda Pharmaceutical <4502.T>", "keywords": [{"text": "Japanese drugmaker Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday", "keywords": [{"text": "EU antitrust approval"}, {"text": "overseas acquisition"}, {"text": "Japanese company"}, {"text": "bid"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "two people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "sentence": " BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company", "keywords": [{"text": "EU antitrust approval"}, {"text": "drugmaker Takeda Pharmaceutical"}, {"text": "overseas acquisition"}, {"text": "Japanese company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "to divest Shire Plc's pipeline compound SHP647 along with some associated rights", "keywords": [{"text": "pipeline compound SHP647"}, {"text": "Shire Plc"}, {"text": "associated rights"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "offer", "tense": "past"}, "text": "offered", "normalized": "offer"}}, {"subject": {"text": "the European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "overlap"}, {"text": "concerns"}, {"text": "drug"}], "entities": [{"type": "Person", "text": "Entyvio"}]}, "action": {"verb": {"text": "voice", "tense": "past"}, "text": "voiced", "normalized": "voice"}}, {"subject": {"text": "Entyvio, a treatment for Crohn's disease and ulcerative colitis,", "keywords": [{"text": "ulcerative colitis"}, {"text": "Crohn"}, {"text": "Entyvio"}, {"text": "treatment"}], "entities": [{"type": "Person", "text": "Entyvio"}, {"type": "HealthCondition", "text": "Crohn's disease"}, {"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "object": {"text": "Takeda's biggest-selling drug", "keywords": [{"text": "Takeda"}, {"text": "biggest-selling drug"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Person", "text": "Entyvio"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda is looking to the acquisition to boost its late-stage pipeline.", "object": {"text": "to the acquisition to boost its late-stage pipeline", "keywords": [{"text": "late-stage pipeline"}, {"text": "acquisition"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "is looking", "normalized": "be look"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda is looking to the acquisition to boost its late-stage pipeline.", "object": {"text": "its late-stage pipeline", "keywords": [{"text": "late-stage pipeline"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "Rare disease specialist Shire", "keywords": [{"text": "disease specialist Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "sentence": " Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "object": {"text": "seven drug candidates in Phase 3 clinical trials compared to its three", "keywords": [{"text": "drug candidates"}, {"text": "clinical trials"}, {"text": "Phase"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal would also make it a global top 10 drugmaker.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "would also make", "normalized": "would also make"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "scheduled to rule on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "to rule on the deal by Nov. 20", "keywords": [{"text": "deal"}, {"text": "Nov."}], "entities": []}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "rule", "tense": "future"}, "text": "is scheduled to rule", "normalized": "be schedule to rule"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire did not immediately respond to a request for comment.", "object": {"text": "not immediately respond to a request for comment", "keywords": [{"text": "comment"}, {"text": "request"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "did", "normalized": "do"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire did not immediately respond to a request for comment.", "object": {"text": "to a request for comment", "keywords": [{"text": "comment"}, {"text": "request"}]}, "action": {"verb": {"text": "respond", "tense": "past", "negated": true}, "text": "respond", "normalized": "respond"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured unconditional clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "unconditional clearance"}, {"text": "United States"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["GeographicFeature", "Country", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "unconditional clearance", "keywords": [{"text": "unconditional clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.973869, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "European Union", "relevance": 0.770255, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "Crohn's disease", "relevance": 0.739649, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Inflammatory bowel disease", "relevance": 0.700049, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "European Commission", "relevance": 0.622192, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Colonoscopy", "relevance": 0.549958, "dbpedia_resource": "http://dbpedia.org/resource/Colonoscopy"}, {"text": "Gastroenterology", "relevance": 0.518397, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Biopsy", "relevance": 0.513114, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}, {"text": "Japan", "relevance": 0.504127, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Helminthic therapy", "relevance": 0.498998, "dbpedia_resource": "http://dbpedia.org/resource/Helminthic_therapy"}, {"text": "Brussels", "relevance": 0.48736, "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}, {"text": "United States", "relevance": 0.483721, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "European Parliament", "relevance": 0.432789, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "German language", "relevance": 0.425651, "dbpedia_resource": "http://dbpedia.org/resource/German_language"}, {"text": "Pharmacology", "relevance": 0.42157, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "European Council", "relevance": 0.421197, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}, {"text": "Colitis", "relevance": 0.397306, "dbpedia_resource": "http://dbpedia.org/resource/Colitis"}, {"text": "Autoimmune diseases", "relevance": 0.393588, "dbpedia_resource": "http://dbpedia.org/resource/Autoimmune_diseases"}, {"text": "Belgium", "relevance": 0.388876, "dbpedia_resource": "http://dbpedia.org/resource/Belgium"}, {"text": "Inflammation", "relevance": 0.386922, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "United Kingdom", "relevance": 0.38012, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "European Coal and Steel Community", "relevance": 0.376067, "dbpedia_resource": "http://dbpedia.org/resource/European_Coal_and_Steel_Community"}, {"text": "Clinical trial", "relevance": 0.374763, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "European Economic Community", "relevance": 0.368705, "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.368633, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Colon", "relevance": 0.364481, "dbpedia_resource": "http://dbpedia.org/resource/Colon_(anatomy)"}, {"text": "Infliximab", "relevance": 0.364323, "dbpedia_resource": "http://dbpedia.org/resource/Infliximab"}, {"text": "People's Republic of China", "relevance": 0.36353, "dbpedia_resource": "http://dbpedia.org/resource/People's_Republic_of_China"}], "categories": [{"score": 0.604417, "label": "/health and fitness/disease"}, {"score": 0.469421, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.425206, "label": "/health and fitness/therapy"}], "relations": [{"type": "ownerOf", "sentence": "Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources Friday, November 09, 2018 11:33 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.627474, "arguments": [{"text": "its", "location": [170, 173], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "headquarters", "location": [178, 190], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.574188, "arguments": [{"text": "Takeda", "location": [560, 566], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "compound", "location": [606, 614], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "employedBy", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.676579, "arguments": [{"text": "Shire Plc", "location": [585, 594], "entities": [{"type": "Person", "text": "Shire Plc"}]}, {"text": "pipeline", "location": [597, 605], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "ownerOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.395012, "arguments": [{"text": "pipeline", "location": [597, 605], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [606, 614], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "hasAttribute", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.711646, "arguments": [{"text": "SHP647", "location": [615, 621], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "inflammatory bowel disease", "location": [742, 768], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "agentOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.981533, "arguments": [{"text": "European Commission", "location": [666, 685], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "voiced", "location": [686, 692], "entities": [{"type": "EventCommunication", "text": "voiced"}]}]}, {"type": "hasAttribute", "sentence": "Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "score": 0.913236, "arguments": [{"text": "Crohn", "location": [810, 815], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [818, 825], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "score": 0.791143, "arguments": [{"text": "Crohn", "location": [810, 815], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "ulcerative colitis", "location": [830, 848], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "affectedBy", "sentence": "Takeda is looking to the acquisition to boost its late-stage pipeline.", "score": 0.576553, "arguments": [{"text": "its", "location": [930, 933], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "acquisition", "location": [909, 920], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "score": 0.454557, "arguments": [{"text": "specialist", "location": [968, 978], "entities": [{"type": "Person", "text": "Shire Plc"}]}, {"text": "disease", "location": [960, 967], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "populationOf", "sentence": "Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "score": 0.167088, "arguments": [{"text": "three", "location": [1054, 1059], "entities": [{"type": "Cardinal", "text": "three"}]}, {"text": "its", "location": [1050, 1053], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "locatedAt", "sentence": "Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources Friday, November 09, 2018 11:33 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.955258, "arguments": [{"text": "headquarters", "location": [178, 190], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [194, 199], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "score": 0.580836, "arguments": [{"text": "regulators", "location": [1344, 1354], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "United States", "location": [1362, 1375], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "(Reporting by Foo Yun Chee; Editing by Elaine Hardcastle) More From Business", "score": 0.560311, "arguments": [{"text": "Foo Yun Chee", "location": [1416, 1428], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "Reporting", "location": [1403, 1412], "entities": [{"type": "EventCommunication", "text": "Reporting"}]}]}, {"type": "residesIn", "sentence": "(Reporting by Foo Yun Chee; Editing by Elaine Hardcastle) More From Business", "score": 0.65787, "arguments": [{"text": "Foo Yun Chee", "location": [1416, 1428], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "Editing", "location": [1430, 1437], "entities": [{"type": "GeopoliticalEntity", "text": "Editing"}]}]}, {"type": "locatedAt", "sentence": "Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources Friday, November 09, 2018 11:33 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.956553, "arguments": [{"text": "Tokyo", "location": [194, 199], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [201, 206], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.610675, "arguments": [{"text": "Foo Yun Chee", "location": [259, 271], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "BRUSSELS", "location": [272, 280], "entities": [{"type": "GeopoliticalEntity", "text": "BRUSSELS"}]}]}, {"type": "employedBy", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.425401, "arguments": [{"text": "drugmaker", "location": [302, 311], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Reuters", "location": [282, 289], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.486651, "arguments": [{"text": "drugmaker", "location": [302, 311], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Japanese", "location": [293, 301], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.973826, "arguments": [{"text": "company", "location": [487, 494], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [478, 486], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.74795, "arguments": [{"text": "people", "location": [500, 506], "entities": [{"type": "Person", "text": "people"}]}, {"text": "said", "location": [532, 536], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical <4502.T> is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.987908, "arguments": [{"text": "Friday", "location": [540, 546], "entities": [{"type": "Date", "text": "Friday"}]}, {"text": "said", "location": [532, 536], "entities": [{"type": "EventCommunication", "text": "said"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": 0.0369539, "label": "positive"}, "relevance": 0.908437}, {"text": "Foo Yun Chee", "sentiment": {"score": 0.48963, "label": "positive"}, "relevance": 0.888101}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0.269622, "label": "positive"}, "relevance": 0.869255}, {"text": "Japanese drugmaker Takeda", "sentiment": {"score": 0.269622, "label": "positive"}, "relevance": 0.835806}, {"text": "disease specialist Shire", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.662344}, {"text": "EU antitrust approval", "sentiment": {"score": 0.269622, "label": "positive"}, "relevance": 0.659928}, {"text": "EST FILE PHOTO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646449}, {"text": "EU competition enforcer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.628556}, {"text": "REUTERS/Kim Kyung-Hoon/File Photo", "sentiment": {"score": 0.439013, "label": "positive"}, "relevance": 0.627659}, {"text": "pipeline compound SHP647", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.626634}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.622893}, {"text": "Shire deal", "sentiment": {"score": 0.415128, "label": "positive"}, "relevance": 0.620487}, {"text": "Shire Plc", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.575964}, {"text": "EU approval", "sentiment": {"score": 0.415128, "label": "positive"}, "relevance": 0.572271}, {"text": "late-stage pipeline", "sentiment": {"score": 0.745809, "label": "positive"}, "relevance": 0.532513}, {"text": "new headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531835}, {"text": "ulcerative colitis", "sentiment": {"score": -0.586548, "label": "negative"}, "relevance": 0.528674}, {"text": "Elaine Hardcastle", "sentiment": {"score": 0.537029, "label": "positive"}, "relevance": 0.526221}, {"text": "unconditional clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524069}, {"text": "overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520774}, {"text": "Japanese company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517841}, {"text": "associated rights", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.517438}, {"text": "European Commission", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.51724}, {"text": "biggest-selling drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514237}, {"text": "drug candidates", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.512138}, {"text": "clinical trials", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.511783}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510993}, {"text": "Friday", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450107}, {"text": "Entyvio", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.437451}, {"text": "overlap", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.429068}, {"text": "Crohn", "sentiment": {"score": -0.586548, "label": "negative"}, "relevance": 0.42445}, {"text": "comment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423735}, {"text": "sources", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421962}, {"text": "logo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42163}, {"text": "bid", "sentiment": {"score": 0.269622, "label": "positive"}, "relevance": 0.42136}, {"text": "BRUSSELS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421037}, {"text": "Tokyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420344}, {"text": "regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420259}, {"text": "London", "sentiment": {"score": 0.269622, "label": "positive"}, "relevance": 0.419697}, {"text": "people", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419575}, {"text": "treatment", "sentiment": {"score": -0.586548, "label": "negative"}, "relevance": 0.418885}, {"text": "request", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418449}, {"text": "matter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418208}, {"text": "China", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418133}, {"text": "Phase", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.418091}]}, "extracted_metadata": {"sha1": "e892056706a9a7fec6ac0b7be32e996dc5c1ee38", "filename": "1541785165420.zip-e7fe7731a2114c5d7d69b4e2cad58815.xml", "file_type": "json"}, "title": "Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources | News | WKZO"}, {"id": "VJsAV0QEB1Qgafz5c46BUFTUvlnpq5Xm0CIt7CXGTALG-Sy5xeCMT_BizOYBT8Rn", "result_metadata": {"score": 31.564947}, "author": "Reuters", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0.439519, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "EU regulators", "keywords": [{"text": "EU regulators"}], "entities": [{"type": "Organization", "text": "EU"}]}, "sentence": "Exclusive: EU regulators to clear $62 billion Takeda, Shire deal: source", "object": {"text": "$62 billion Takeda, Shire deal", "keywords": [{"text": "Shire deal"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "clear", "tense": "future"}, "text": "to clear", "normalized": "to clear"}}], "concepts": [{"text": "European Union", "relevance": 0.896, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}], "categories": [{"score": 0.519048, "label": "/finance/financial news"}, {"score": 0.490472, "label": "/finance/investing"}, {"score": 0.490472, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "Exclusive: EU regulators to clear $62 billion Takeda, Shire deal: source", "score": 0.755683, "arguments": [{"text": "regulators", "location": [14, 24], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "EU", "location": [11, 13], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Exclusive: EU regulators to clear $62 billion Takeda, Shire deal: source", "score": 0.613386, "arguments": [{"text": "regulators", "location": [14, 24], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "$62 billion", "location": [34, 45], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "EU regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.944951}, {"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858599}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.746947}, {"text": "source", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481285}]}, "crawl_date": "2018-11-09T18:42:35Z", "url": "https://sg.finance.yahoo.com/news/eu-regulators-clear-62-billion-takeda-shire-deal-163720406--finance.html", "host": "sg.finance.yahoo.com", "text": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "main_image_url": "https://s.yimg.com/uu/api/res/1.2/co3BnX8tsn5INXdPqiKw.A--~B/aD0zMjA7dz00NTA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en_us/News/Reuters/2018-11-09T163720Z_1_LYNXNPEEA81E3_RTROPTP_2_TAKEDA-PHARMA-RESULTS.JPG", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T18:11:00-06:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.0446631, "label": "negative"}, "text": "Takeda", "relevance": 0.959599, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.696723, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.574603, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.476033, "type": "Person"}, {"count": 2, "sentiment": {"score": 0.444623, "label": "positive"}, "text": "Foo Yun Chee", "relevance": 0.475677, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.629599, "label": "negative"}, "text": "Shire Plc", "relevance": 0.330345, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.302827, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": -0.522828, "label": "negative"}, "text": "Shire", "relevance": 0.296488, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.282607, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.270254, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 3, "sentiment": {"score": -0.629599, "label": "negative"}, "text": "Entyvio", "relevance": 0.264961, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.257984, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.254943, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": -0.351942, "label": "negative"}, "text": "United States", "relevance": 0.240413, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.586548, "label": "negative"}, "text": "Crohn's disease", "relevance": 0.211879, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BRUSSELS", "relevance": 0.207969, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"count": 1, "sentiment": {"score": -0.586548, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.207812, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": 0.589684, "label": "positive"}, "text": "Elaine Hardcastle", "relevance": 0.185689, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.629599, "label": "negative"}, "text": "European Commission", "relevance": 0.18401, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.589684, "label": "positive"}, "text": "Susan Fenton", "relevance": 0.180094, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.156113, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.143298, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.28 percent", "relevance": 0.143298, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62", "relevance": 0.143298, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0348106, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "Tokyo FILE PHOTO"}, {"text": "Takeda Pharmaceutical"}, {"text": "new headquarters"}, {"text": "logo"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co"}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}, {"subject": {"text": "Japanese drugmaker Takeda Pharmaceutical", "keywords": [{"text": "Japanese drugmaker Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday", "keywords": [{"text": "EU antitrust approval"}, {"text": "overseas acquisition"}, {"text": "Japanese company"}, {"text": "bid"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"type": "Person", "text": "Shire"}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Japanese drugmaker Takeda Pharmaceutical", "keywords": [{"text": "Japanese drugmaker Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "is set to win", "normalized": "be set to win"}}, {"subject": {"text": "two people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "sentence": " BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "object": {"text": "Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company", "keywords": [{"text": "EU antitrust approval"}, {"text": "drugmaker Takeda Pharmaceutical"}, {"text": "overseas acquisition"}, {"text": "Japanese company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"type": "Person", "text": "Shire"}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "to divest Shire Plc's pipeline compound SHP647 along with some associated rights", "keywords": [{"text": "pipeline compound SHP647"}, {"text": "Shire Plc"}, {"text": "associated rights"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "offer", "tense": "past"}, "text": "offered", "normalized": "offer"}}, {"subject": {"text": "the European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "object": {"text": "concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "overlap"}, {"text": "concerns"}, {"text": "drug"}], "entities": [{"type": "Person", "text": "Entyvio"}]}, "action": {"verb": {"text": "voice", "tense": "past"}, "text": "voiced", "normalized": "voice"}}, {"subject": {"text": "Entyvio, a treatment for Crohn's disease and ulcerative colitis,", "keywords": [{"text": "ulcerative colitis"}, {"text": "Crohn"}, {"text": "Entyvio"}, {"text": "treatment"}], "entities": [{"type": "Person", "text": "Entyvio"}, {"type": "HealthCondition", "text": "Crohn's disease"}, {"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "object": {"text": "Takeda's biggest-selling drug", "keywords": [{"text": "Takeda"}, {"text": "biggest-selling drug"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Person", "text": "Entyvio"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shire's shares", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire's shares moved into positive territory in London following the Reuters story, closing up 0.28 percent.", "object": {"text": "into positive territory", "keywords": [{"text": "positive territory"}]}, "action": {"verb": {"text": "move", "tense": "past"}, "text": "moved", "normalized": "move"}}, {"subject": {"text": "Its U.S. listed shares", "keywords": [{"text": "U.S."}, {"text": "shares"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Its U.S. listed shares recovered some earlier losses after the story.", "object": {"text": "some earlier losses", "keywords": [{"text": "earlier losses"}]}, "action": {"verb": {"text": "recover", "tense": "past"}, "text": "recovered", "normalized": "recover"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda is looking to the acquisition to boost its late-stage pipeline.", "object": {"text": "to the acquisition to boost its late-stage pipeline", "keywords": [{"text": "late-stage pipeline"}, {"text": "acquisition"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "is looking", "normalized": "be look"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda is looking to the acquisition to boost its late-stage pipeline.", "object": {"text": "its late-stage pipeline", "keywords": [{"text": "late-stage pipeline"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "Rare disease specialist Shire", "keywords": [{"text": "disease specialist Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "sentence": " Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "object": {"text": "seven drug candidates in Phase 3 clinical trials compared to its three", "keywords": [{"text": "drug candidates"}, {"text": "clinical trials"}, {"text": "Phase"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal would also make it a global top 10 drugmaker.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "would also make", "normalized": "would also make"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "scheduled to rule on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "to rule on the deal by Nov. 20", "keywords": [{"text": "deal"}, {"text": "Nov."}], "entities": []}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "The EU competition enforcer", "keywords": [{"text": "EU competition enforcer"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " The EU competition enforcer, which is scheduled to rule on the deal by Nov. 20, and Takeda declined to comment.", "object": {"text": "on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "rule", "tense": "future"}, "text": "is scheduled to rule", "normalized": "be schedule to rule"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire did not immediately respond to a request for comment.", "object": {"text": "not immediately respond to a request for comment", "keywords": [{"text": "comment"}, {"text": "request"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "did", "normalized": "do"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire did not immediately respond to a request for comment.", "object": {"text": "to a request for comment", "keywords": [{"text": "comment"}, {"text": "request"}]}, "action": {"verb": {"text": "respond", "tense": "past", "negated": true}, "text": "respond", "normalized": "respond"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured unconditional clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "unconditional clearance"}, {"text": "United States"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "unconditional clearance", "keywords": [{"text": "unconditional clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.962898, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Crohn's disease", "relevance": 0.732427, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "European Union", "relevance": 0.72025, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "Inflammatory bowel disease", "relevance": 0.695713, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "European Commission", "relevance": 0.555418, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Colonoscopy", "relevance": 0.534741, "dbpedia_resource": "http://dbpedia.org/resource/Colonoscopy"}, {"text": "Biopsy", "relevance": 0.508778, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}, {"text": "Gastroenterology", "relevance": 0.499789, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Japan", "relevance": 0.493967, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Helminthic therapy", "relevance": 0.48545, "dbpedia_resource": "http://dbpedia.org/resource/Helminthic_therapy"}, {"text": "United States", "relevance": 0.444867, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Pharmacology", "relevance": 0.406008, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Brussels", "relevance": 0.402592, "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}, {"text": "Colitis", "relevance": 0.393433, "dbpedia_resource": "http://dbpedia.org/resource/Colitis"}, {"text": "Inflammation", "relevance": 0.38672, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Autoimmune diseases", "relevance": 0.382414, "dbpedia_resource": "http://dbpedia.org/resource/Autoimmune_diseases"}, {"text": "Clinical trial", "relevance": 0.36331, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "London", "relevance": 0.361102, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.358888, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Infliximab", "relevance": 0.354401, "dbpedia_resource": "http://dbpedia.org/resource/Infliximab"}, {"text": "Colon", "relevance": 0.353262, "dbpedia_resource": "http://dbpedia.org/resource/Colon_(anatomy)"}], "categories": [{"score": 0.611019, "label": "/health and fitness/disease"}, {"score": 0.457922, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.429746, "label": "/health and fitness/therapy"}], "relations": [{"type": "ownerOf", "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.604009, "arguments": [{"text": "its", "location": [61, 64], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "headquarters", "location": [69, 81], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "ownerOf", "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.640249, "arguments": [{"text": "its", "location": [146, 149], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "headquarters", "location": [154, 166], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.696523, "arguments": [{"text": "people", "location": [467, 473], "entities": [{"type": "Person", "text": "people"}]}, {"text": "said", "location": [499, 503], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.986569, "arguments": [{"text": "Friday", "location": [507, 513], "entities": [{"type": "Date", "text": "Friday"}]}, {"text": "said", "location": [499, 503], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.677799, "arguments": [{"text": "Takeda", "location": [527, 533], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "compound", "location": [573, 581], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "partOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.823661, "arguments": [{"text": "pipeline", "location": [564, 572], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Shire Plc", "location": [552, 561], "entities": [{"type": "Organization", "text": "Shire Plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "ownerOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.407276, "arguments": [{"text": "pipeline", "location": [564, 572], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [573, 581], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "agentOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.558545, "arguments": [{"text": "SHP647", "location": [582, 588], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "voiced", "location": [653, 659], "entities": [{"type": "EventCommunication", "text": "voiced"}]}]}, {"type": "hasAttribute", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.658327, "arguments": [{"text": "SHP647", "location": [582, 588], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "inflammatory bowel disease", "location": [709, 735], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "agentOf", "sentence": "Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.", "score": 0.927477, "arguments": [{"text": "European Commission", "location": [633, 652], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "voiced", "location": [653, 659], "entities": [{"type": "EventCommunication", "text": "voiced"}]}]}, {"type": "hasAttribute", "sentence": "Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "score": 0.913236, "arguments": [{"text": "Crohn", "location": [777, 782], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [785, 792], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.", "score": 0.791143, "arguments": [{"text": "Crohn", "location": [777, 782], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "ulcerative colitis", "location": [797, 815], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "locatedAt", "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.935396, "arguments": [{"text": "headquarters", "location": [69, 81], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [85, 90], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.950581, "arguments": [{"text": "headquarters", "location": [154, 166], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [170, 175], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "Shire's shares moved into positive territory in London following the Reuters story, closing up 0.28 percent.", "score": 0.702301, "arguments": [{"text": "territory", "location": [886, 895], "entities": [{"type": "GeopoliticalEntity", "text": "BRUSSELS"}]}, {"text": "London", "location": [899, 905], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "affectedBy", "sentence": "Takeda is looking to the acquisition to boost its late-stage pipeline.", "score": 0.576553, "arguments": [{"text": "its", "location": [1076, 1079], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "acquisition", "location": [1055, 1066], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "score": 0.454557, "arguments": [{"text": "specialist", "location": [1114, 1124], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "disease", "location": [1106, 1113], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "populationOf", "sentence": "Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three.", "score": 0.167088, "arguments": [{"text": "three", "location": [1200, 1205], "entities": [{"type": "Cardinal", "text": "three"}]}, {"text": "its", "location": [1196, 1199], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "locatedAt", "sentence": "Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "score": 0.580836, "arguments": [{"text": "regulators", "location": [1490, 1500], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "United States", "location": [1508, 1521], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "(Reporting by Foo Yun Chee; Editing by Elaine Hardcastle and Susan Fenton)", "score": 0.560311, "arguments": [{"text": "Foo Yun Chee", "location": [1562, 1574], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "Reporting", "location": [1549, 1558], "entities": [{"type": "EventCommunication", "text": "Reporting"}]}]}, {"type": "residesIn", "sentence": "(Reporting by Foo Yun Chee; Editing by Elaine Hardcastle and Susan Fenton)", "score": 0.65787, "arguments": [{"text": "Foo Yun Chee", "location": [1562, 1574], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "Editing", "location": [1576, 1583], "entities": [{"type": "GeopoliticalEntity", "text": "Editing"}]}]}, {"type": "basedIn", "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.411556, "arguments": [{"text": "its", "location": [146, 149], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "Tokyo", "location": [170, 175], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "1 / 2 FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.935807, "arguments": [{"text": "Tokyo", "location": [170, 175], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [177, 182], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.610675, "arguments": [{"text": "Foo Yun Chee", "location": [235, 247], "entities": [{"type": "Person", "text": "Foo Yun Chee"}]}, {"text": "BRUSSELS", "location": [248, 256], "entities": [{"type": "GeopoliticalEntity", "text": "BRUSSELS"}]}]}, {"type": "employedBy", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.357552, "arguments": [{"text": "drugmaker", "location": [278, 287], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Reuters", "location": [258, 265], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.793673, "arguments": [{"text": "drugmaker", "location": [278, 287], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Japanese", "location": [269, 277], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.923028, "arguments": [{"text": "Shire", "location": [395, 400], "entities": [{"type": "Facility", "text": "Shire"}]}, {"text": "London", "location": [386, 392], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "basedIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Foo Yun Chee BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.", "score": 0.967282, "arguments": [{"text": "company", "location": [454, 461], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [445, 453], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.917818}, {"text": "Foo Yun Chee", "sentiment": {"score": 0.444624, "label": "positive"}, "relevance": 0.879131}, {"text": "drugmaker Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.817497}, {"text": "disease specialist Shire", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.64687}, {"text": "Tokyo FILE PHOTO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63606}, {"text": "REUTERS/Kim Kyung-Hoon/File Photo", "sentiment": {"score": 0.444624, "label": "positive"}, "relevance": 0.630075}, {"text": "EU antitrust approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627609}, {"text": "pipeline compound SHP647", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.619287}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.616458}, {"text": "new headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614897}, {"text": "EU competition enforcer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604379}, {"text": "Shire Plc", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.568064}, {"text": "Reuters story", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525748}, {"text": "late-stage pipeline", "sentiment": {"score": 0.745809, "label": "positive"}, "relevance": 0.524381}, {"text": "ulcerative colitis", "sentiment": {"score": -0.586548, "label": "negative"}, "relevance": 0.524354}, {"text": "Elaine Hardcastle", "sentiment": {"score": 0.589684, "label": "positive"}, "relevance": 0.51919}, {"text": "unconditional clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517109}, {"text": "overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51625}, {"text": "Japanese company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514795}, {"text": "associated rights", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.514392}, {"text": "European Commission", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.514218}, {"text": "earlier losses", "sentiment": {"score": -0.351942, "label": "negative"}, "relevance": 0.513853}, {"text": "biggest-selling drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511712}, {"text": "positive territory", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509942}, {"text": "drug candidates", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.506412}, {"text": "clinical trials", "sentiment": {"score": -0.522828, "label": "negative"}, "relevance": 0.506259}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505753}, {"text": "Susan Fenton", "sentiment": {"score": 0.589684, "label": "positive"}, "relevance": 0.505538}, {"text": "London", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436855}, {"text": "Entyvio", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.436608}, {"text": "logo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436234}, {"text": "deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435741}, {"text": "shares", "sentiment": {"score": -0.351942, "label": "negative"}, "relevance": 0.435642}, {"text": "overlap", "sentiment": {"score": -0.629599, "label": "negative"}, "relevance": 0.427671}, {"text": "Crohn", "sentiment": {"score": -0.586548, "label": "negative"}, "relevance": 0.423292}, {"text": "comment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421776}, {"text": "percent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421769}, {"text": "bid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420289}, {"text": "BRUSSELS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419942}, {"text": "people", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419043}, {"text": "regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418853}, {"text": "treatment", "sentiment": {"score": -0.586548, "label": "negative"}, "relevance": 0.418412}, {"text": "Friday", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41809}, {"text": "U.S.", "sentiment": {"score": -0.351942, "label": "negative"}, "relevance": 0.417896}, {"text": "request", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417565}, {"text": "matter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417307}, {"text": "China", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417277}]}, "extracted_metadata": {"sha1": "bb9e73a0e355739d2f9c978e98e90c49b235d75a", "filename": "1541788955289.zip-2ec890e4ad5ed267b9c4d5d31814ed08.xml", "file_type": "json"}, "title": "Exclusive: EU regulators to clear $62 billion Takeda, Shire deal: source", "forum_title": "Yahoo Finance - Business finance, stock market, quotes, news"}]}